Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Mar. 03, 2022 | Jun. 30, 2021 | |
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2021 | ||
Document Transition Report | false | ||
Entity File Number | 001-39801 | ||
Entity Registrant Name | XOMA CORPORATION | ||
Entity Incorporation State Country Code | DE | ||
Entity Tax Identification Number | 52-2154066 | ||
Entity Address Address Line1 | 2200 Powell Street | ||
Entity Address Address Line2 | Suite 310 | ||
Entity Address City Or Town | Emeryville | ||
Entity Address State Or Province | CA | ||
Entity Address Postal Zip Code | 94608 | ||
City Area Code | 510 | ||
Local Phone Number | 204-7200 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 240,018,070 | ||
Entity Common Stock, Shares Outstanding | 11,319,124 | ||
Auditor Firm ID | 34 | ||
Auditor Name | DELOITTE & TOUCHE LLP | ||
Auditor Location | San Francisco, California | ||
Entity Central Index Key | 0000791908 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Common Stock | |||
Security12b Title | Common Stock, $0.0075 par value | ||
Trading Symbol | XOMA | ||
Security Exchange Name | NASDAQ | ||
8.625% Series A Cumulative, Perpetual Preferred Stock | |||
Security12b Title | 8.625% Series A Cumulative, Perpetual Preferred Stock, par value $0.05 | ||
Trading Symbol | XOMAP | ||
Security Exchange Name | NASDAQ | ||
Series B Depositary Shares | |||
Security12b Title | Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05) | ||
Trading Symbol | XOMAO | ||
Security Exchange Name | NASDAQ |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash | $ 93,328 | $ 84,222 |
Restricted cash | 2,049 | 1,611 |
Short-term equity securities | 774 | |
Trade and other receivables, net | 209 | 263 |
Income tax receivable | 1,526 | |
Prepaid expenses and other current assets | 613 | 443 |
Total current assets | 96,973 | 88,065 |
Long-term restricted cash | 531 | |
Property and equipment, net | 13 | 21 |
Operating lease right-of-use assets | 200 | 359 |
Long-term royalty and commercial payment receivables | 69,075 | 34,575 |
Long-term equity securities | 1,693 | |
Other assets - long term | 301 | 41 |
Total assets | 166,562 | 125,285 |
Current liabilities: | ||
Accounts payable | 1,072 | 456 |
Accrued and other liabilities | 525 | 642 |
Income taxes payable | 91 | |
Contingent consideration under RPAs and CPPAs | 8,075 | 75 |
Operating lease liabilities | 195 | 179 |
Unearned revenue recognized under units-of-revenue method | 1,641 | 1,452 |
Contingent liabilities | 0 | 1,410 |
Current portion of long-term debt | 8,088 | |
Preferred stock dividend accrual | 1,368 | |
Total current liabilities | 12,967 | 12,302 |
Unearned revenue recognized under units-of-revenue method - long-term | 11,685 | 13,516 |
Long-term debt | 12,764 | |
Long-term operating lease liabilities | 34 | 229 |
Other liabilities - long term | 50 | |
Total liabilities | 24,686 | 38,861 |
Commitments and Contingencies (Note 13) | ||
Stockholders' equity: | ||
Preferred Stock | ||
Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,315,263 and 11,228,792 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively | 85 | 84 |
Additional paid-in capital | 1,307,030 | 1,267,377 |
Accumulated deficit | (1,165,288) | (1,181,086) |
Total stockholders' equity | 141,876 | 86,424 |
Total liabilities and stockholders' equity | 166,562 | 125,285 |
8.625% Series A Cumulative, Perpetual Preferred Stock | ||
Stockholders' equity: | ||
Preferred Stock | 49 | 49 |
8.375% Series B Cumulative, Perpetual Preferred Stock | ||
Stockholders' equity: | ||
Preferred Stock | ||
Convertible preferred stock | ||
Stockholders' equity: | ||
Preferred Stock |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Preferred stock, par value (in dollars per share) | $ 0.05 | $ 0.05 |
Preferred stock, shares authorized (in shares) | 1,000,000 | 1,000,000 |
Common stock, par value (in dollars per share) | $ 0.0075 | $ 0.0075 |
Common stock, shares authorized (in shares) | 277,333,332 | 277,333,332 |
Common stock, shares issued (in shares) | 11,315,263 | 11,228,792 |
Common stock, shares outstanding (in shares) | 11,315,263 | 11,228,792 |
8.625% Series A Cumulative, Perpetual Preferred Stock | ||
Preferred stock, par value (in dollars per share) | $ 0.05 | $ 0.05 |
Preferred stock, shares authorized (in shares) | 984,000 | 984,000 |
Preferred stock, dividend rate (as a percent) | 8.625% | 8.625% |
Preferred stock, shares issued (in shares) | 984,000 | 984,000 |
Preferred stock, shares outstanding (in shares) | 984,000 | 984,000 |
8.375% Series B Cumulative, Perpetual Preferred Stock | ||
Preferred stock, par value (in dollars per share) | $ 0.05 | $ 0.05 |
Preferred stock, shares authorized (in shares) | 3,600 | |
Preferred stock, dividend rate (as a percent) | 8.375% | 8.375% |
Preferred stock, shares issued (in shares) | 1,600 | 0 |
Preferred stock, shares outstanding (in shares) | 1,600 | 0 |
Convertible preferred stock | ||
Preferred stock, shares issued (in shares) | 5,003 | 5,003 |
Preferred stock, shares outstanding (in shares) | 5,003 | 5,003 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues: | ||
Revenue from contracts with customers | $ 36,518 | $ 27,941 |
Revenue recognized under units-of-revenue method | 1,642 | 1,444 |
Total revenues | 38,160 | 29,385 |
Operating expenses: | ||
Research and development | 171 | 170 |
General and administrative | 20,460 | 16,799 |
Total operating expenses | 20,631 | 16,969 |
Income from operations | 17,529 | 12,416 |
Other (expense) income, net: | ||
Interest expense | (461) | (1,844) |
Loss on extinguishment of debt | (300) | |
Other (expense) income, net | (879) | 1,225 |
Income before income tax | 15,889 | 11,797 |
Income tax (expense) benefit | (91) | 1,501 |
Net income | 15,798 | 13,298 |
Net comprehensive income | 15,798 | 13,298 |
Net income and comprehensive income available to common stockholders (Note 11), basic | 7,787 | 8,793 |
Net income and comprehensive income available to common stockholders (Note 11), diluted | $ 7,968 | $ 9,010 |
Basic net income per share available to common stockholders (in dollars per share) | $ 0.69 | $ 0.82 |
Diluted net income per share available to common stockholders (in dollars per share) | $ 0.65 | $ 0.78 |
Weighted average shares used in computing basic net income per share available to common stockholders | 11,288 | 10,674 |
Weighted average shares used in computing diluted net income per share available to common stockholders | 12,192 | 11,503 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Preferred Stock8.625% Series A Cumulative, Perpetual Preferred Stock | Preferred Stock8.375% Series B Cumulative, Perpetual Preferred Stock | Preferred StockConvertible preferred stock | Common Stock | Additional Paid-In Capital [Member] | Accumulated Deficit [Member] | Total |
Balance at beginning of period at Dec. 31, 2019 | $ 73 | $ 1,238,299 | $ (1,194,384) | $ 43,988 | |||
Balance at beginning of period (in shares) at Dec. 31, 2019 | 6,000 | 9,759,000 | |||||
Increase (Decrease) in Stockholders' Equity | |||||||
Issuance of stock | $ 49 | 22,572 | 22,621 | ||||
Issuance of stock, net (in shares) | 984,000 | ||||||
Issuance of common stock related to Series Y preferred stock conversion | $ 10 | (10) | |||||
Issuance of common stock related to Series Y preferred stock conversion (in shares) | (1,000) | 1,253,000 | |||||
Stock-based compensation expense | 3,961 | 3,961 | |||||
Exercise of stock options | $ 1 | 2,406 | 2,407 | ||||
Exercise of stock options (in shares) | 211,000 | ||||||
Issuance of common stock related to 401(k) contribution and ESPP | 136 | 136 | |||||
Issuance of common stock related to 401(k) contribution and ESPP (in shares) | 6,000 | ||||||
Disgorgement of stockholder's short-swing profits | 13 | 13 | |||||
Net income and comprehensive income | 13,298 | 13,298 | |||||
Balance at end of period at Dec. 31, 2020 | $ 49 | $ 84 | 1,267,377 | (1,181,086) | 86,424 | ||
Balance at end of period (in shares) at Dec. 31, 2020 | 984,000 | 5,000 | 11,229,000 | ||||
Increase (Decrease) in Stockholders' Equity | |||||||
Issuance of stock | 37,140 | 37,140 | |||||
Issuance of stock, net (in shares) | 2,000 | ||||||
Preferred stock dividends | (4,867) | (4,867) | |||||
Stock-based compensation expense | 6,195 | 6,195 | |||||
Exercise of stock options | $ 1 | 1,052 | $ 1,053 | ||||
Exercise of stock options (in shares) | 77,000 | 77,305 | |||||
Exercise of common stock warrants (in shares) | 5,000 | ||||||
Issuance of common stock related to 401(k) contribution and ESPP | 133 | $ 133 | |||||
Issuance of common stock related to 401(k) contribution and ESPP (in shares) | 4,000 | ||||||
Net income and comprehensive income | 15,798 | 15,798 | |||||
Balance at end of period at Dec. 31, 2021 | $ 49 | $ 85 | $ 1,307,030 | $ (1,165,288) | $ 141,876 | ||
Balance at end of period (in shares) at Dec. 31, 2021 | 984,000 | 2,000 | 5,000 | 11,315,000 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands | 12 Months Ended | |
Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | |
Cash flows from operating activities: | ||
Net income | $ 15,798 | $ 13,298 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Stock-based compensation expense | 6,195 | 3,961 |
Common stock contribution to 401(k) | 90 | 88 |
Depreciation | 7 | 22 |
Amortization of debt issuance costs, debt discount and final payment on debt | 200 | 698 |
Non-cash portion of Novartis Milestone Payment | (7,300) | |
Reduction of contingent NIH refund liability | (105) | |
Non-cash lease expense | 160 | 150 |
Loss on extinguishment of debt | 300 | |
Change in fair value of equity securities | 919 | (1,012) |
Changes in assets and liabilities: | ||
Trade and other receivables, net | 54 | 2,670 |
Income tax receivable | 1,526 | (1,526) |
Prepaid expenses and other assets | (169) | 83 |
Accounts payable and accrued liabilities | 765 | (542) |
Income tax payable | 91 | |
Operating lease liabilities | (179) | (163) |
Unearned revenue recognized under units-of-revenue method | (1,642) | (1,444) |
Contingent NIH refund liability | (1,305) | 612 |
Other liabilities | (27) | 497 |
Net cash provided by operating activities | 22,678 | 10,092 |
Cash flows from investing activities: | ||
Payments related to purchase of royalty rights and other commercial payment rights | (26,500) | (1,200) |
Receipts related to purchased royalty rights | 1,000 | |
Purchase of property and equipment | (9) | |
Net cash used in investing activities | (26,500) | (209) |
Cash flows from financing activities: | ||
Proceeds from issuance of preferred stock | 40,000 | 24,600 |
Payment of preferred and common stock issuance costs | (3,385) | (1,945) |
Proceeds from exercise of options and other share-based compensation | 1,584 | 4,850 |
Principal payments - debt | (4,250) | (5,313) |
Payment for extinguishment of debt | (17,103) | |
Payment for preferred stock dividends | (3,499) | |
Taxes paid related to net share settlement of equity awards | (488) | (2,395) |
Other | (24) | (4) |
Net cash provided by financing activities | 12,835 | 19,793 |
Net increase in cash and restricted cash | 9,013 | 29,676 |
Cash and restricted cash at the beginning of the period | 86,364 | 56,688 |
Cash and restricted cash at the end of the period | 95,377 | 86,364 |
Supplemental Cash Flow Information: | ||
Cash paid for interest | 311 | 692 |
Non-cash investing and financing activities: | ||
Estimated fair value of contingent consideration under the Affitech CPPA | 8,000 | |
Preferred stock dividend accrual | $ 1,368 | |
Interest added to principal balance on long-term debt | 490 | |
Accrued cost related to issuance of capital stock | $ 264 |
Description of Business
Description of Business | 12 Months Ended |
Dec. 31, 2021 | |
Description of Business | |
Description of Business | 1. Description of Business XOMA (referred to as “XOMA” or the “Company”), a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. The Company’s portfolio was built through licensing its proprietary products and platforms from its legacy discovery and development business, combined with the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. Liquidity and Financial Condition The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December 31, 2021, the Company had unrestricted and restricted cash of $93.3 million and $2.0 million, respectively. The restricted cash balance may only be used to pay dividends on the outstanding Series A Preferred Stock and the outstanding Series B Preferred Stock (Note 12). In June 2021, the Company repaid its outstanding debt obligations to SVB and Novartis, for a total of $17.1 million (Note 8). Based on the Company’s current cash balance and its ability to control discretionary spending, such as royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these consolidated financial statements are issued. |
Basis of Presentation and Signi
Basis of Presentation and Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Basis of Presentation and Significant Accounting Policies | |
Basis of Presentation and Significant Accounting Policies | 2. Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X. Use of Estimates The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts and amortization of the payments received from HCRP. Under the Company’s contracts with the NIAID, a part of the NIH, the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. As of December 31, 2020, the audit procedures were completed, and the Company adjusted its estimated liability owed to NIH to $1.4 million. In December 2021, the NIH completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and the Company adjusted its liability owed to NIH to $1.3 million. In December 2021, the Company paid the final approved refund liability of $1.3 million. As such, no contingent liability remained on the Company’s consolidated balance sheets as of December 31, 2021. In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. The COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements. Cash and Restricted Cash Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2021 and 2020, the Company did not have any cash equivalent balances, defined as highly liquid financial instruments purchased with original maturities of three months or less. Restricted cash consists of bank deposits held to pay dividends on the Company’s Series A Preferred Stock and Series B Preferred Stock. The Company maintains cash and restricted cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash and restricted cash. The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Year Ended December 31, 2021 2020 Cash $ 93,328 $ 84,222 Restricted cash 2,049 2,142 Total cash and restricted cash $ 95,377 $ 86,364 Revenue Recognition The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied. The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products. License of intellectual property If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time). Milestone payments At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Royalties For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. Sale of Future Revenue Streams The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment. Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period. Stock-Based Compensation The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. Equity Securities The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive income in the period of sale. In October 2020, Rezolute completed a 1:50 Purchase of Rights to Future Milestones, Royalties and Commercial Payments The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive income. The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2021 and December 31, 2020. Leases The Company leases its headquarters office space in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length. Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive income. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. Income Taxes The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable. The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. Prior Period Reclassifications Within the consolidated statement of cash flows, the Company presented principal payments on its finance lease and proceeds from disgorgement of stockholder's short-swing profits together in order for the prior period to conform with current period presentation. Net Income per Share Attributable to Common Stockholders The Company calculates basic and diluted income per share attributable to common stockholders using the two-class method. The Company’s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities. Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period and any deemed dividends related to beneficial conversion features on convertible preferred stock, if applicable, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income per share attributable to common stockholders is then calculated by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding. Diluted net income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock. The calculation of diluted net income per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options or warrants, the presumed exercise of such securities are dilutive to net income per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and therefore, are not included in the diluted shares until the contingency is resolved. Comprehensive Income Comprehensive income is comprised of two components: net income and other comprehensive income. Other comprehensive income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net income. The Company did not record any transactions within other comprehensive income in the periods presented and, therefore, the net income and comprehensive income were the same for all periods presented. Accounting Pronouncements Recently Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. , on January 1, 2021. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments of adopting this new accounting guidance In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations – Accounting for Contract Assets and Contact Liabilities from Contracts with Customers |
Consolidated Financial Statemen
Consolidated Financial Statement Detail | 12 Months Ended |
Dec. 31, 2021 | |
Consolidated Financial Statement Detail | |
Consolidated Financial Statement Detail | 3. Consolidated Financial Statement Detail Equity Securities As of December 31, 2021 and December 31, 2020, equity securities consisted of an investment in Rezolute’s common stock of $0.8 million and $1.7 million, respectively (Note 4). For the years ended December 31, 2021 and December 31, 2020, the Company recognized a loss of $0.9 million and a gain of $1.0 million, respectively, due to the change in fair value of its investment in Rezolute’s common stock in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income. Accrued and Other Liabilities Accrued and other liabilities consisted of the following (in thousands): December 31, December 31, 2021 2020 Accrued legal and accounting fees 295 351 Accrued payroll and benefits 135 136 Accrued incentive compensation 55 71 Other accrued liabilities 40 84 Total $ 525 $ 642 |
Licensing and Other Arrangement
Licensing and Other Arrangements | 12 Months Ended |
Dec. 31, 2021 | |
Licensing and Other Arrangements | |
Licensing and Other Arrangements | 4. Licensing and Other Arrangements Novartis – Anti-TGFβ Antibody (NIS793) On September 30, 2015, the Company and Novartis entered into the Anti-TGFβ Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company’s anti-transforming growth factor beta (“TGFβ”) antibody program (now “NIS793”). Under the terms of the Anti-TGFβ Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGFβ Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’s royalty obligations end. The Anti-TGFβ Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGFβ Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days’ notice. The Company concluded that there were multiple promised goods and services under the Anti-TGFβ Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December 31, 2015 The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGFβ Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGFβ Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment which was recognized as license fees in the consolidated statement of operations and comprehensive income. The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid single-digit percentage rate to up to a low double-digit percentage rate. Novartis’s obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country. On October 21, 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis’ first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGFβ Antibody License Agreement, the Company received $17.7 million in cash and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis. On October 20, 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis’ first NIS793 Phase 3 clinical trial. The Company is eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGFβ Antibody License Agreement. As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company recognized $35.0 million and $25.0 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the years ended December 31, 2021 and 2020, respectively. Novartis – Anti-IL-1β Antibody (VPM087) and IL-1 Beta On August 24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (“VPM087”), a novel anti-Interleukin-1 (“IL-1”) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. On August 24, 2017, pursuant to a separate agreement (the “IL-1 Target License Agreement”), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the “Exclusivity Option”) to such intellectual property for the treatment and prevention of cardiovascular disease. Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company’s outstanding debt with Les Laboratories Servier (“Servier”) (the “Servier Loan”). In addition, Novartis extended the maturity date on the Company’s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company’s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August 24, 2017, resulting in a $0.2 million premium paid to the Company. Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company’s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid single-digits. Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months’ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point. At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the year ended December 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority. The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2021 and 2020. Takeda On November 1, 2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda. Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and TAK-169, and low single-digit royalties on future sales of all products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 13.5 years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration). In February 2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent. As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. During the years ended December 31, 2021 and 2020, the Company recognized annual license fee revenue of $0.1 million from Takeda. On November 16, 2020, the first patient was dosed in Takeda’s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda. The Company is eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement. During the years ended December 31, 2021 and 2020, the Company recognized $0.1 million and $2.1 million, respectively, as revenue from contracts with customers in the consolidated statement of operations and comprehensive income. Rezolute On December 6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now “RZ358”) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities. Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute’s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute’s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued. Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute’s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical testing. Rezolute’s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee’s obligation to make payments to Rezolute based on sales of such product in such country The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days’ notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents. No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute’s financing activities. The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute’s achievement of financing activities and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute’s common stock. As of December 31, 2021 and December 31, 2020, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2021 and 2020. The Company reassessed the development and regulatory milestones and concluded that such variable consideration is fully constrained and excluded from the transaction price as of December 31, 2021 and 2020. Janssen Biotech The Company and Janssen were parties to a license agreement which was terminated in 2017. The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019 as it had completed its performance obligation. The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen’s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. In May 2021, the Company earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets. In December 2021, the Company earned a $0.2 million milestone pursuant to its agreement with Janssen. As of December 31, 2021 and December 31, 2020, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. Milestone revenue of $0.7 million and $0.4 million was recognized for the years ended December 31, 2021 and 2020, respectively. Affimed In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE The Company concluded that the commercial milestone payments are solely dependent on Affimed’s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. As of December 31, 2021, there were no contract assets or contract liabilities NIAID Prior to the sale of the Company’s biodefense business in 2016, the Company performed services under contracts funded with federal funds from NIAID including under a $64.8 million multiple-year contract (Contract No. HHSN272200800028C), for development of anti-botulinum antibody product candidates and a $28.0 million multiple-year contract (Contract No. HHSN272201100031C) for development of broad-spectrum antitoxins for the treatment of human botulism poisoning. The contract work was being performed on a cost plus fixed fee basis over a three-year period. The Company recognized revenue under the arrangement as the services were performed on a proportional performance basis. Consistent with the Company’s other contracts with the U.S. government, invoices were provisional until finalized. The Company operated under provisional rates from 2010 through 2015, subject to adjustment based on actual rates upon agreement with the government. In 2014, upon completion of NIAID’s review of hours and external expenses, XOMA agreed to exclude certain hours and external expenses resulting in a $0.4 million receivable and $0.8 million deferred revenue balances. As of December 31, 2017, the Company wrote off the $0.4 million receivable from NIAID as the likelihood of collection was remote. In October of 2019, NIH, which includes NIAID, notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. The KPMG testing procedures were completed in December 2020. As a result, the Company recognized $1.4 million as estimated refund liabilities owed to NIH on the consolidated balance sheet as of December 31, 2020. The additional $0.6 million liability was recognized as a reduction of revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the year ended December 31, 2020. In December 2021, NIH completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and approved a finalized refund liability of $1.3 million. The $0.1 million reduction in the liability, from its previously recorded $1.4 million estimate, was recognized as revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the year ended December 31, 2021. In December 2021, the Company paid the finalized refund liability owed to NIH of $1.3 million and no balance of the contingent liability remained on the consolidated balance sheets as of December 31, 2021. Sale of Future Revenue Streams On December 21, 2016, the Company entered into two royalty interest sale agreements (together, the “Royalty Sale Agreements”) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December 2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million. The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under units-of-revenue method over the life of the license agreements because of the Company’s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company’s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period’s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product. The Company recognized $1.6 million and $1.4 million as revenue under units-of-revenue method under these arrangements during the years ended December 31, 2021 and December 31, 2020, respectively. As of December 31, 2020, the current and non-current portion of the remaining unearned revenue recognized under units-of-revenue method was $1.5 million and $13.5 million, respectively. As of December 31, 2021, the Company classified $1.6 million and $11.7 million as current and non-current unearned revenue recognized under units-of-revenue method, respectively. |
Royalty and Commercial Payment
Royalty and Commercial Payment Purchase Agreements | 12 Months Ended |
Dec. 31, 2021 | |
Royalty and Commercial Payment Purchase Agreements | |
Royalty and Commercial Payment Purchase Agreements | 5. Royalty and Commercial Payment Purchase Agreements Royalty Purchase Agreement with Agenus On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (“Incyte”) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentage of applicable net sales. In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company’s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements. Under the terms of the Agenus RPA, the Company paid Agenus $15.0 million. At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. In November 2020, MK-4830 advanced into Phase 2 development and Agenus earned a $10.0 million clinical development milestone under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance. The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. Royalty Purchase Agreement with Bioasis On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product. Under the terms of the Bioasis RPA, the Company paid $0.3 million and will make contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the “Bioasis Contingent Consideration”). At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $0.1 million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income. As of December 31, 2021, there was no change in the fair value of the contingent consideration from its initial value and no amounts were paid during the year ended December 31, 2021. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights. At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under the Second Bioasis RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. Royalty Purchase Agreement with Aronora On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the “Non-Royalties”) related to five anti-thrombotic hematology drug candidates. Three candidates were subject to Aronora’s collaboration with Bayer (the “Bayer Products”), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the “non-Bayer Products”) for which the Company will receive low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Company’s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products. Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB (Note 8). The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the “Aronora Contingent Consideration”). Pursuant to the Aronora RPA, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the “Royalty Milestones”). The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product. Royalties per product in excess of $250.0 million are retained by the Company. At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. Royalty Purchase Agreement with Palobiofarma On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin’s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the “Palo Licensed Products”) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. Under the terms of the Palo RPA, the Company paid Palo a $10.0 million payment at the close of the transaction which occurred simultaneously upon parties’ entry into the Palo RPA on September 26, 2019. At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. Royalty Purchase Agreement with Viracta On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. Royalty Purchase Agreement with Kuros On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals’ vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestones. At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. Commercial Payment Purchase Agreement with Affitech On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche’s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones (Note 15). At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which includes the $6.0 million upfront payment and $8.0 million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million meet the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable. Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. The following table summarizes the long-term royalty receivable activities including acquisitions of royalty rights, commercial payment rights and cash receipts for achievement of contractual milestones during the years ended December 31, 2021 and 2020 (in thousands): Balance at January 1, 2020 $ 34,375 Acquisition of royalty rights: Bioasis 1,200 Cash receipts for achievement of contractual milestones: Agenus (1,000) Balance at December 31, 2020 34,575 Acquisition of royalty and commercial payment rights: Viracta 13,500 Kuros 7,000 Affitech 14,000 Balance at December 31, 2021 $ 69,075 |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Measurements | |
Fair Value Measurements | 6. Fair Value Measurements The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company’s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions. The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): Fair Value Measurements at December 31, 2021 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Assets: Equity securities $ 774 $ — $ — $ 774 Liabilities: Contingent consideration under RPAs and CPPAs $ — $ — $ 8,075 $ 8,075 Fair Value Measurements at December 31, 2020 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Assets: Equity securities $ — $ — $ 1,693 $ 1,693 Liabilities: Contingent consideration $ — $ — $ 75 $ 75 Transfers to and from Levels 1, 2, and 3 are recognized at the end of the reporting period. On June 30, 2021, the Company’s equity investment in Rezolute’s common stock transferred from Level 3 to Level 1. In reporting periods prior to June 30, 2021, the Company applied an illiquidity discount to the fair value of Rezolute’s common stock due to the lack of trading volume, resulting in classification as Level 3 June 30, 2021 1 2020 Equity Securities The following table reconciles the beginning and ending balance for the Level 3 financial assets recurring fair value measurement for the year ended December 31, 2021 (in thousands): Year Ended December 31, 2021 Balance at December 31, 2019 $ 681 Change in fair value 1,012 Balance at December 31, 2020 $ 1,693 Change in fair value 617 Transfer out of Level 3 as of June 30, 2021 (2,310) Balance at December 31, 2021 $ — The equity securities consisted of an investment in Rezolute’s common stock and are classified on the consolidated balance sheets as current assets as of December 31, 2021, and long-term assets as of December 31, 2020. The reclassification from noncurrent to current assets was due to the equity securities achieving sufficient and consistent trading volume on the Nasdaq Stock Market during the second quarter of 2021. The equity securities are revalued each reporting period with changes in fair value recorded in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income. As of December 31, 2020, the Company and its valuation specialist, valued the equity securities using the closing price for Rezolute’s common stock traded on the Nasdaq Stock Market and adjusted for an illiquidity discount. The inputs that were used to calculate the illiquidity discount were based on observable and unobservable estimates and judgments and therefore were classified as a Level 3 fair value measurement. As the Company has the right and option to sell up to 100,000 shares of Rezolute’s common stock back to Rezolute after December 31, 2019 (Note 4), the fair value of the equity securities was determined by dividing the total shares of Rezolute’s common stock held by the Company into two tranches based on the estimated time to a potential liquidity event. As of December 31, 2021, the Company valued the equity securities using the closing price for Rezolute’s common stock traded on the Nasdaq Stock Market. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement. The closing price of Rezolute’s common stock as per the Nasdaq Stock Market was $4.78 and $11.99 as of December 31, 2021 and December 31, 2020, respectively. The estimated fair value of the equity securities as of December 31, 2020 was calculated based on the following assumptions: December 31, December 31, 2021 2020 Closing common stock price $ 4.78 $ 11.99 Tranche 1: Discount for lack of marketability N/A (1) % 12 % Estimated time to liquidity of shares 0.25 year Tranche 2: Discount for lack of marketability N/A (1) % 14 % Estimated time to liquidity of shares 0.67 years (1) Due to sufficient and consistent trading volume, the equity investment will be measured at the closing price per the Nasdaq Stock Market. The assumptions related to the unobservable inputs identified above, and any changes in those assumptions thereto, will no longer be considered in determining the fair value of the equity securities. Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the equity securities. Contingent Consideration The estimated fair value of the contingent consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. The estimated fair value of the contingent consideration liability at the inception of the Affitech CPPA represents the future consideration that is contingent upon the achievement of specified regulatory milestones. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving regulatory milestones. Changes in the fair value of the liability for contingent consideration will be recorded in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income until settlement. As of December 31, 2021 |
Lease Agreement
Lease Agreement | 12 Months Ended |
Dec. 31, 2021 | |
Lease Agreement | |
Lease Agreement | 7. Lease Agreement The Company leases one facility in Emeryville, California under an operating lease that expires in February 2023. The Emeryville lease contains an option to extend the lease for an additional term, however, the Company is not reasonably certain to exercise this option. The following table summarizes maturity of the Company’s operating lease liabilities as of December 31, 2021 (in thousands): Operating Undiscounted lease payments Leases 2022 202 2023 34 2024 — Total undiscounted lease payments 236 Present value adjustment (7) Total net lease liabilities $ 229 The following table summarizes the cost components of the Company’s operating lease for the years ended December 31, 2021 and 2020, respectively (in thousands): Year Ended December 31, 2021 2020 Lease costs: Operating lease cost $ 177 $ 177 Variable lease cost (1) 8 7 Total lease costs $ 185 $ 184 (1) The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Year Ended December 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows under operating leases $ 196 $ 189 The present value assumptions used in calculating the present value of the lease payments for the Company’s operating lease as of December 31, 2021 and December 31, 2020 were as follows: December 31, December 31, 2021 2020 Weighted-average remaining lease term 1.17 years 2.17 years Weighted-average discount rate 5.51 % 5.51 % |
Long-Term Debt and Other Financ
Long-Term Debt and Other Financings | 12 Months Ended |
Dec. 31, 2021 | |
Long-Term Debt and Other Financings | |
Long-Term Debt and Other Financings | 8. Long-Term Debt and Other Financings SVB Loan On May 7, 2018 (the “Effective Date”), the Company executed the SVB Loan Agreement with SVB. Under the Loan Agreement, upon the Company’s request, SVB made advances (each, a “Term Loan Advance”) available to the Company up to $20.0 million (the “Term Loan”). The Company was allowed to borrow advances under the Term Loan from the Effective Date until the earlier of March 31, 2019 or an event of default (the “Draw Period”). The interest rate was calculated at a rate equal to the greater of (i) 4.75%, or (ii) 0.25% plus the prime rate as reported from time to time in The Wall Street Journal. Payments under the Loan Agreement were interest only until the first anniversary of the funding date of each Term Loan Advance. The interest-only period was followed by equal monthly payments of principal and interest over 24 months. Each Term Loan Advance was scheduled to mature at the earlier of (i) the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii) March 1, 2023, or (iii) 30 days prior to the earliest maturity of any portion of the Company’s loan with Novartis (the “Loan Maturity Date”). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed. The entire principal balance, including a final payment fee equal to 8.5% of the original principal, was due and payable on the Loan Maturity Date. In June 2021, the Company repaid its principal balance of $6.5 million and paid the 8.5% final payment fee of $1.4 million to SVB. The Company also paid SVB a prepayment fee of 1% of the outstanding principal balance. In connection with the Loan Agreement, the Company issued a warrant to SVB which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share (the “Warrant”). The Warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the Warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. In addition, the Company incurred debt issuance costs of $0.2 million in connection with the Loan Agreement. On March 4, 2019, the Loan Agreement was amended to extend the Draw Period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. Both warrants may be exercised on a cashless basis and are exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. As of December 31, 2021, both warrants are outstanding. In September 2018, the Company borrowed advances of $7.5 million under the Loan Agreement in connection with the Agenus RPA (Note 5). The Company recorded a discount of $0.3 million against the debt, which was being amortized to interest expense over the term of the Term Loan Advance using the effective interest method. During the year ended December 31, 2019, the Company borrowed advances totaling $9.5 million under the Loan Agreement in connection with the Aronora RPA, Palo RPA and payment of the Aronora Contingent Consideration (Note 5). The Company recorded a discount of $45,000 against the debt, which was being amortized to interest expense over the term of the Term Loan Advance using the effective interest method. The Company recorded $0.2 million of non-cash interest expense resulting from the amortization of the discount and accretion of the final payment before the loan was extinguished in June 2021 and $0.6 million for the year ended December 31, 2020. As of December 31, 2020, the carrying value of the debt under the Loan Agreement was $11.8 million. Of this amount, $8.1 million was classified as current portion of long-term debt and $3.7 million was classified as long-term debt on the consolidated balance sheet. In June 2021, the Company paid off its entire outstanding principal balance to SVB. Upon repayment of the principal balance, the Company recognized a loss on extinguishment of $0.3 million in other (expense) income, net of the consolidated statement of operations for the year ended December 31, 2021. As of December 31, 2021, there was no carrying value of the debt under the Loan Agreement. Novartis Note In May 2005, the Company executed the Novartis Note Agreement with Novartis, which was due and payable in full in June 2015. Under the Novartis Note Agreement, the Company borrowed semi-annually to fund up to 75% of the Company’s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50.0 million in aggregate principal amount. Interest on the principal amount of the loan accrued at six-month LIBOR plus 2% and the interest rate reset in June and December annually. Accrued interest was payable semi-annually in June and December of each year or, at the Company’s election, the semi-annual interest payments could be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount did not exceed $50.0 million. The Company made this election for all interest payments. Loans under the Novartis Note Agreement were secured by the Company’s interest in its collaboration with Novartis, including any payments owed to it thereunder. In June 2021, the Company repaid its outstanding principal balance to Novartis of $9.1 million and extinguished its debt obligation. On September 30, 2015, concurrent with the execution of a license agreement with Novartis as discussed in Note 4, XOMA and Novartis, who assumed the rights to the note from Novartis Vaccines Diagnostics, Inc. executed an amendment to the Novartis Note Agreement (the “Secured Novartis Note Amendment”) under which the parties extended the maturity date of the note from September 30, 2015 to September 30, 2020, and eliminated the mandatory prepayment previously required to be made with certain proceeds of pre-tax profits and royalties. In addition, upon achievement of a specified development and regulatory milestone, the then-outstanding principal amount of the note was to be reduced by $7.3 million rather than the Company receiving such amount as a cash payment. On September 22, 2017, in connection with the Gevokizumab License Agreement with Novartis, the Company and Novartis executed an amendment to the Novartis Secured Note Amendment under which the parties further extended the maturity date of the Novartis Secured Note Amendment from September 30, 2020 to September 30, 2022. On October 21, 2020, the first patient was dosed in Novartis’s first NIS793 Phase 2 clinical trial and the Company earned a $25.0 million milestone pursuant to the Anti-TGFβ Antibody License Agreement, of which $17.7 million was received in cash and $7.3 million was recognized as a reduction to the debt obligation to Novartis. As of December 31, 2020, the outstanding principal balance under the Novartis Secured Note Amendment was $9.1 million and was included in long-term debt in the accompanying consolidated balance sheet. In June 2021, the Company repaid its entire outstanding debt balance to Novartis. The repayment of principal did not result in any gain or loss on extinguishment. As of December 31, 2021, there was no carrying value of the debt under the Novartis Note Agreement. Interest Expense Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive income for the years ended December 31, 2021 and 2020, relates to the following debt instruments (in thousands): Year Ended December 31, 2021 2020 SVB Loan $ 373 $ 1,365 Novartis Note 88 477 Other — 2 Total interest expense $ 461 $ 1,844 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Taxes | |
Income Taxes | 9. Income Taxes The Company has pre-tax book income of $15.9 million and $11.8 million for the year ended December 31, 2021 and 2020, respectively. The Company has $0.1 million income tax expense and $1.5 million income tax benefit for the years ended December 31, 2021 and 2020, respectively. The provision (benefit) for income taxes, all classified as current, consists of the following (in thousands): Year Ended December 31, 2021 2020 Federal $ 91 $ (1,501) State — — Total $ 91 $ (1,501) Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company’s actual effective income tax rate is as follows: Year Ended December 31, 2021 2020 Federal tax at statutory rate 21 % 21 % Stock compensation and other permanent differences 9 % (6) % Federal orphan drug credit (2) % — % Tax benefit related to CARES Act — % (13) % Tax benefit related to net operating loss carryforward utilization (11) % — % Valuation allowance (16) % (15) % Total 1 % (13) % On March 27, 2020, the CARES Act was enacted, which includes a five-year NOL carryback provision which enabled the Company to benefit from certain losses at the former federal tax rate of 34%. In 2020, the Company recorded tax benefits of $1.5 million related to the NOL carryback provision. During the year ended December 31, 2021, the Company received $1.5 million in cash for its income tax receivable. The significant components of net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands): December 31, 2021 2020 Capitalized research and development expenses $ 7,822 $ 11,500 Net operating loss carryforwards 17,657 17,638 Research and development and other tax credit carryforwards 13,125 13,454 Stock compensation 4,778 5,158 Unearned revenue 2,817 3,462 Other 807 401 Total deferred tax assets 47,006 51,613 Valuation allowance (47,006) (51,613) Net deferred tax assets $ — $ — The net decrease in the valuation allowance was $4.6 million and $3.9 million, for the years ended December 31, 2021 and 2020, respectively. Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company’s four sources of taxable income including historical operating performance and the repeal of NOL carryback, the Company has determined that total deferred tax assets should be fully offset by a valuation allowance. Based on an analysis under Section 382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to annual limitations), the Company experienced an ownership change in February 2017 which substantially limits the future use of its pre-change NOLs and certain other pre-change tax attributes per year. The Company has excluded the related tax attributes that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2021 and December 31, 2020. To the extent that the Company does not utilize its carryforwards within the applicable statutory carryforward periods, either because of Section 382 limitations or the lack of sufficient taxable income, the carryforwards will expire unused. As of December 31, 2021, the Company had federal NOL carry-forwards of approximately $78.8 million and state NOL carry-forwards of approximately $38.1 million to offset future taxable income. $13.6 million of federal NOL carryforwards will begin to expire in 2036 and the remainder may be carried forward indefinitely. The state NOL carryforwards will begin to expire in 2033. The Company had federal orphan credit of $2.0 million which if not utilized will expire in 2037. The Company also had $19.8 million of California research and development tax credits which have no expiration date. Under the 2017 federal income tax law, as modified by the federal tax law changes enacted in March 2020, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but, for taxable years beginning after December 31, 2020, the deductibility of such federal NOLs may only be utilized to offset 80% of taxable income annually. The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company’s federal income tax returns for tax years 2018 and beyond remain subject to examination by the Internal Revenue Service. The Company’s state income tax returns for tax years 2017 and beyond remain subject to examination by state tax authorities. In addition, all of the NOLs and research and development credit carryforwards that may be used in future years are still subject to adjustment. The following table summarizes the Company’s activity related to its unrecognized tax benefits (in thousands): Year Ended December 31, 2021 2020 Balance at January 1 $ 5,938 $ 5,517 Increase related to current year tax position — — Increase related to prior year tax position — 421 Balance at December 31 $ 5,938 $ 5,938 As of December 31, 2021, the Company had a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as the Company currently has a full valuation allowance against its deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future. The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through December 31, 2021, the Company has not accrued interest or penalties related to uncertain tax positions. |
Stock Based Compensation
Stock Based Compensation | 12 Months Ended |
Dec. 31, 2021 | |
Stock Based Compensation | |
Stock Based Compensation | 10. Stock Based Compensation The Company may grant qualified and non-qualified stock options, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company’s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. Employee Stock Purchase Plan In May 2015, the Company’s stockholders approved the 2015 Employee Stock Purchase Plan (the “2015 ESPP”), which replaced the Company’s legacy 1998 ESPP. Under the 2015 ESPP, the Company reserved 15,000 shares of common stock for issuance as of its effective date of July 1, 2015, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The 2015 ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2015 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. In February 2017, the Compensation Committee and the Board of Directors adopted, and in May 2017, the Company’s stockholders approved, an amendment to the Company’s 2015 ESPP. The amendment (a) increased by 250,000 the shares of common stock (from 15,000 shares to a total of 265,000 shares) available for issuance under the 2015 ESPP; and (b) increased the maximum number of shares of common stock an employee may purchase in any offering period to 2,500. As of December 31, 2021, the Company had 237,072 remaining authorized shares available for purchase under the ESPP. During the years ended December 31, 2021 and 2020, employees purchased 2,225 and 2,746 shares of common stock, respectively, under the 2015 ESPP. Deferred Savings Plan Under section 401(k) of the Internal Revenue Code of 1986, the Board of Directors adopted, effective June 1, 1987, a tax-qualified deferred compensation plan for employees of the Company. Participants may make contributions which defer up to 50%of their eligible compensation per payroll period, up to a maximum for 2021 and 2020 of $19,500 (or $26,000 for employees over 50 years of age). The Company may, at its sole discretion, make contributions each plan year, in cash or in shares of the Company’s common stock, in amounts which match up to 50% of the salary deferred by the participants. The expense related to these contributions was $0.1 million for the years ended December 31, 2021 and December 31, 2020, and 100% was paid in common stock for each year. The Company applies shares from plan forfeitures of terminated employees toward the Company’s matching contribution. Stock Option Plans In May 2010, the Compensation Committee and Board of Directors adopted, and in July 2010 the Company’s stockholders approved the 2010 Plan. The 2010 Plan was amended in 2016, 2017 and 2019 to (a) increase the number of shares of common stock issuable under the 2010 Plan; (b) increase the number of shares of common stock issuable under the 2010 Plan as incentive stock options; and (c) extend the term of the 2010 Plan to April 1, 2029. As of December 31, 2021, the number of shares of common stock reserved for issuance under the 2010 Plan is 3,029,062 shares. From the 2010 Plan, the Company grants stock options to eligible employees, consultants and directors. Stock-based awards granted under the 2010 Plan may be exercised when vested and generally expire ten years from the date of the grant or three As of December 31, 2021, the Company had 161,140 shares available for grant under the 2010 Plan. As of December 31, 2021, options to purchase 1,911,177 shares of common stock were outstanding under the 2010 Plan. Stock Options Stock options generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. Stock Option Plans Summary The following table summarizes the Company’s stock option activity for the year ended December 31, 2021. As of December 31, 2021 Weighted Weighted Average Average Aggregate Exercise Contractual Intrinsic Number of Price Term Value shares Per Share (in years) (in thousands) Outstanding at January 1, 2021 1,827,906 $ 20.66 6.31 $ 51,401 Granted 325,211 32.02 Exercised (77,305) 13.61 Forfeited, expired or cancelled (164,635) 46.59 Outstanding at December 31, 2021 1,911,177 $ 20.64 6.33 $ 15,103 Exercisable at December 31, 2021 1,553,696 $ 18.75 5.69 $ 14,894 The aggregate intrinsic value of stock options exercised in 2021 and 2020 was $1.6 million and $5.4 million, respectively. The weighted-average grant-date fair value per share of the options granted in 2021 and 2020 was $22.23 and $18.41, respectively. As of December 31, 2021, $4.1 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.21 years. Stock-based Compensation Expense The fair value of stock options granted during the years ended December 31, 2021 and 2020, was estimated based on the following weighted average assumptions for: Year Ended December 31, 2021 2020 Dividend yield 0 % 0 % Expected volatility 83 % 100 % Risk-free interest rate 0.95 % 0.72 % Expected term 5.66 years 5.64 years The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive income (in thousands): Year Ended December 31, 2021 2020 Research and development $ — $ — General and administrative 6,195 3,961 Total stock-based compensation expense $ 6,195 $ 3,961 |
Net Income Per Share Attributab
Net Income Per Share Attributable to Common Stockholders | 12 Months Ended |
Dec. 31, 2021 | |
Net Income Per Share Attributable to Common Stockholders | |
Net Income Per Share Attributable to Common Stockholders | 11. Net Income Per Share Attributable to Common Stockholders Potentially dilutive securities are excluded from the calculation of diluted net income per share attributable to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income per share attributable to common stockholders (in thousands): Year Ended December 31, 2021 2020 Convertible preferred stock — — Common stock options 479 616 Warrants for common stock — 6 Total 479 622 The following is a reconciliation of the numerator (net income) and denominator (number of shares) used in the calculation of basic and diluted net income per share attributable to common stockholders (in thousands): Year Ended December 31, 2021 2020 Numerator Net income $ 15,798 $ 13,298 Less: Series A accumulated dividends (2,122) (88) Less: Series B accumulated dividends (2,438) — Less: Allocation of undistributed earnings to participating securities (3,451) (4,417) Net income available to common stockholders, basic $ 7,787 $ 8,793 Add: Adjustments to undistributed earnings allocated to participating securities 181 217 Net income available to common stockholders, diluted $ 7,968 $ 9,010 Denominator Weighted average shares used in computing basic net income per share available to common stockholders 11,288 10,674 Effect of dilutive stock options 900 824 Effect of dilutive warrants 4 5 Weighted average shares used in computing diluted net income per share available to common stockholders 12,192 11,503 Basic net income per share available to common stockholders $ 0.69 $ 0.82 Diluted net income per share of common stock $ 0.65 $ 0.78 |
Capital Stock
Capital Stock | 12 Months Ended |
Dec. 31, 2021 | |
Capital Stock | |
Capital Stock | 12. Capital Stock Series X and Series Y Convertible Preferred Stock The Company sold directly to BVF 5,003 shares of Series X convertible preferred stock in 2017 and 1,252.772 shares of Series Y convertible preferred stock in 2018. There were no shares of Series Y convertible preferred stock outstanding as of December 31, 2021, after BVF converted all Series Y preferred stock into common stock on April 15, 2020. As of December 31, 2021 and 2020, there were 5,003 shares authorized and issued of Series X convertible preferred stock. The Series X and Series Y convertible preferred stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State. Dividends— Liquidation Rights— Conversion— Voting Rights— Classification— Beneficial Conversion Feature— Series A Preferred Stock On December 15, 2020, the Company sold 984,000 shares of its 8.625% Series A cumulative, perpetual preferred stock at the price of $25.00 per share, through a public offering for aggregate gross proceeds of $24.6 million. Total offering costs of $2.0 million were offset against the proceeds from the sale of Series A Preferred Stock, for total net proceeds of $22.6 million. Mr. Matthew Perry, a member of the Company’s Board of Directors and President of BVF, purchased 200,000 shares of Series A Preferred Stock in the public offering at the public offering price of $25.00 per share for an aggregate amount of $5.0 million. The spouse of James Neal, the Company’s Chief Executive Officer and , purchased 8,000 shares of the Series A Preferred Stock in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million. As of December 31, 2021 and 2020, there were 984,000 shares authorized and issued of Series A Preferred Stock. The Series A preferred stock have the following characteristics, which are set forth in the Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State. Dividends— the Series A Preferred Stock shall be entitled to receive, when, and if authorized by the Board of Directors and declared by the Corporation, cumulative cash dividends at the rate of 8.625% per annum of the $25.00 liquidation preference per share of the Series A Preferred Stock. Such dividends will accumulate and be cumulative from, and including, the date of original issue of the A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October of each year beginning on or about April 15, 2021. The amount of any dividend payable on the Series A Preferred Stock for any period greater or less than a full Dividend Period shall be prorated and computed on the basis of a 360 -day year consisting of twelve 30 -day months. Liquidation Rights— rank senior to all classes or series of common stock as to dividend rights and rights upon liquidation, dissolution or winding-up and on parity with respect to the of assets with the Company’s Series X Preferred Stock. Redemption and Special Optional Redemption— upon the occurrence of a delisting event or change of control event, the Company may redeem outstanding Series A Preferred Stock at an amount of $25.00 per share. Conversion— Voting Rights— Classification— Depositary Shares Representing Interest in Series B Preferred Stock On April 9, 2021, the Company sold 1,600,000 Series B Depositary Shares, at the price of $25.00 per Series B Depositary Share, through a public offering for aggregate gross proceeds of $40.0 million. Total offering costs of $2.9 million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $37.1 million. The spouse of James Neal, the Chief Executive Officer and Chairman of the Board of Directors, purchased 8,000 shares of the Series B Depositary Shares in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million. As of December 31, 2021, there were 3,600 shares authorized and 1,600 issued of Series B Preferred Stock. The Series B Preferred Stock has the following characteristics, which are set forth in the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock, as corrected, filed with the Delaware Secretary of State. Dividends $2,093.75 per share each year. Such dividends shall be payable quarterly in arrears on or about the 15th calendar day of each January, April, July and October commencing on or about July 15, 2021. The dividends will accumulate and be cumulative from, and including, the date of original issue of the Series B Preferred Stock, on the basis of a 360-day year consisting of twelve 30-day months. Dividends will be payable to holders of record as they appear in the stockholder records of the Company (or the depositary in the case of Series B Depositary Shares representing underlying Series B Preferred Stock) at the close of business on the applicable dividend record date. Liquidation Preference Redemption and Special Redemption Conversion Voting Rights Classification Dividends During the year ended December 31, 2021, the Company’s Board of Directors declared and paid cash dividends on the Company’s Series A Preferred Stock and Series B Depositary shares as follows. Series A Preferred Stock Series B Depositary Share Cash Dividend Declared Cash Dividend Declared Dividend Declaration Date ($ per share) ($ per share) Dividend Payment Date March 17, 2021 $ 0.71875 $ N/A (1) April 15, 2021 May 21, 2021 $ 0.53906 $ 0.55833 July 15, 2021 July 28, 2021 $ 0.53906 $ 0.52344 October 15, 2021 October 20, 2021 $ 0.53906 $ 0.52344 January 18, 2022 (1) The Company sold 1,600,000 Series B Depositary Shares on April 9, 2021. As such, the first dividend was declared on May 21, 2021. As of December 31, 2021, the Company held restricted cash of $2.0 million in a segregated account that may only be used to pay dividends on the Series A and Series B Preferred Stock. BVF Ownership In February 2020, BVF elected to increase the beneficial ownership limitation of the Series Y preferred stock to 50%, which became effective on April 11, 2020. On April 15, 2020, BVF converted all of its shares of Series Y preferred stock into common stock. As of December 31, 2021, BVF owned approximately 31.2% of the Company’s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own 52.3% of the Company’s total outstanding shares of common stock. The Company’s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of December 31, 2021, the contingency was not met, therefore the Series A Preferred Stock is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company. 2018 Common Stock ATM Agreement On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed. 2021 Series B Preferred Stock ATM Agreement On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. Common Stock Warrants As of December 31, 2021 and 2020, the following common stock warrants were outstanding: Exercise Price December 31, December 31, Issuance Date Expiration Date Balance Sheet Classification per Share 2021 2020 February 2016 February 2021 Stockholders’ equity $ 15.40 — 8,249 May 2018 May 2028 Stockholders’ equity $ 23.69 6,332 6,332 March 2019 March 2029 Stockholders’ equity $ 14.71 4,845 4,845 11,177 19,426 In February 2016, in conjunction with services provided by a third-party consultant, the Company issued a warrant to purchase up to an aggregate of 8,249 unregistered shares of the Company’s common stock at an exercise price equal to $15.40 per share. The warrant was exercisable immediately and had a five-year term expiring in February 2021. As of December 31, 2020, the estimated fair value of the warrant of $0.1 million was calculated using the Black-Scholes Model and was classified in stockholders’ equity on the consolidated balance sheet. In February 2021, the Company issued 4,917 shares of common stock upon a cashless exercise of the common stock warrants held by Torreya Partners LLC. There is no balance of these warrants on the consolidated balance sheet as of December 31, 2021. In May 2018, the Company issued SVB a warrant in connection with the SVB Loan Agreement (Note 8) which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share. The warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. The warrant is classified in stockholders’ equity on the consolidated balance sheets. In March 2019, the Loan Agreement was amended to extend the Draw Period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The second warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. As of December 31, 2021, both warrants are outstanding and no shares have been issued upon exercise of the warrants. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies | |
Commitments and Contingencies | 13. Commitments and Contingencies Collaborative Agreements, Royalties and Milestone Payments The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company’s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. Contingent Consideration Pursuant to the Company’s royalty and commercial payment purchase agreements with Bioasis, Aronora, Kuros and Affitech, the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones and the Affitech regulatory and sales milestones. The Company recorded $0.1 million and $8.0 million for the Bioasis Contingent Consideration and the Affitech Regulatory Milestones, respectively, which, represents the estimated fair value of these potential future payments at the inception of the respective agreements. The contingent consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other (expense) income, net. As of December 31, 2021, there were no changes in the estimated fair value of the Bioasis Contingent Consideration and the Affitech Sales Milestones from the initial value. The liability for future Aronora Royalty Milestones, Kuros Sales Milestones and Affitech Sales Milestones will be recorded when the amounts, by product, are estimable and probable. As of December 31, 2021, none of these Aronora Royalty Milestones, Kuros Sales Milestones or Affitech Sales Milestones were assessed to be probable and as such, no liability was recorded on the consolidated balance sheet. |
Concentration of Risk, Segment
Concentration of Risk, Segment and Geographic Information | 12 Months Ended |
Dec. 31, 2021 | |
Concentration of Risk, Segment and Geographic Information | |
Concentration of Risk, Segment and Geographic Information | 14. Concentration of Risk, Segment and Geographic Information Concentration of Risk Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the year ended December 31, 2021, one partner represented 92% of total revenues. For the year ended December 31, 2020, one partner represented 85% of total revenues. As of December 31, 2021 and 2020, one partner represented 100% of the trade receivables balance. Segment Information The Company has determined that it operates in one business segment as it only reports operating results on an aggregate basis to the chief operating decision maker of the Company. Geographic Information Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees: Year Ended December 31, 2021 2020 Europe $ 35,000 $ 25,010 United States 2,610 1,275 Asia Pacific 550 3,100 Total $ 38,160 $ 29,385 The Company’s property and equipment is held in the United States. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2021 | |
Subsequent Events | |
Subsequent Events | 15. Subsequent Events On January 28, 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize faricimab (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. Upon approval, the Company became eligible to receive a 0.5% commercial payment stream on net sales associated with faricimab for a ten-year period following its first commercial sale in the United States. The Company acquired this interest under the Affitech CPPA, pursuant to which, the Company paid Affitech a $5.0 million milestone tied to these U.S. marketing approvals. The Company may pay up to an additional $15.0 million to Affitech based on the achievement of certain regulatory approval and sales milestones. In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to XOMA pursuant to the Company’s Rezolute License Agreement. |
Basis of Presentation and Sig_2
Basis of Presentation and Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Basis of Presentation and Significant Accounting Policies | |
Basis of Presentation | Basis of Presentation The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts and amortization of the payments received from HCRP. Under the Company’s contracts with the NIAID, a part of the NIH, the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. As of December 31, 2020, the audit procedures were completed, and the Company adjusted its estimated liability owed to NIH to $1.4 million. In December 2021, the NIH completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and the Company adjusted its liability owed to NIH to $1.3 million. In December 2021, the Company paid the final approved refund liability of $1.3 million. As such, no contingent liability remained on the Company’s consolidated balance sheets as of December 31, 2021. In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. The COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements. |
Cash and Restricted Cash | Cash and Restricted Cash Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2021 and 2020, the Company did not have any cash equivalent balances, defined as highly liquid financial instruments purchased with original maturities of three months or less. Restricted cash consists of bank deposits held to pay dividends on the Company’s Series A Preferred Stock and Series B Preferred Stock. The Company maintains cash and restricted cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash and restricted cash. The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Year Ended December 31, 2021 2020 Cash $ 93,328 $ 84,222 Restricted cash 2,049 2,142 Total cash and restricted cash $ 95,377 $ 86,364 |
Revenue Recognition | Revenue Recognition The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied. The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products. License of intellectual property If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time). Milestone payments At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Royalties For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. |
Sale of Future Revenue Streams | Sale of Future Revenue Streams The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment. Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period. |
Stock-Based Compensation | Stock-Based Compensation The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. |
Equity Securities | Equity Securities The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive income in the period of sale. In October 2020, Rezolute completed a 1:50 |
Purchase of Rights to Future Milestones, Royalties and Commercial Payments | Purchase of Rights to Future Milestones, Royalties and Commercial Payments The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive income. The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2021 and December 31, 2020. |
Leases | Leases The Company leases its headquarters office space in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length. Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive income. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. |
Income Taxes | Income Taxes The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable. The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. |
Prior Period Reclassifications | Prior Period Reclassifications Within the consolidated statement of cash flows, the Company presented principal payments on its finance lease and proceeds from disgorgement of stockholder's short-swing profits together in order for the prior period to conform with current period presentation. |
Net Income per Share Attributable to Common Stockholders | Net Income per Share Attributable to Common Stockholders The Company calculates basic and diluted income per share attributable to common stockholders using the two-class method. The Company’s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities. Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period and any deemed dividends related to beneficial conversion features on convertible preferred stock, if applicable, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income per share attributable to common stockholders is then calculated by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding. Diluted net income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock. The calculation of diluted net income per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options or warrants, the presumed exercise of such securities are dilutive to net income per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and therefore, are not included in the diluted shares until the contingency is resolved. |
Comprehensive Income | Comprehensive Income Comprehensive income is comprised of two components: net income and other comprehensive income. Other comprehensive income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net income. The Company did not record any transactions within other comprehensive income in the periods presented and, therefore, the net income and comprehensive income were the same for all periods presented. |
Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements | Accounting Pronouncements Recently Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. , on January 1, 2021. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments of adopting this new accounting guidance In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations – Accounting for Contract Assets and Contact Liabilities from Contracts with Customers |
Basis of Presentation and Sig_3
Basis of Presentation and Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Basis of Presentation and Significant Accounting Policies | |
Schedule of cash and restricted cash | The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Year Ended December 31, 2021 2020 Cash $ 93,328 $ 84,222 Restricted cash 2,049 2,142 Total cash and restricted cash $ 95,377 $ 86,364 |
Consolidated Financial Statem_2
Consolidated Financial Statement Detail (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Consolidated Financial Statements | |
Accrued and Other Liabilities | Accrued and other liabilities consisted of the following (in thousands): December 31, December 31, 2021 2020 Accrued legal and accounting fees 295 351 Accrued payroll and benefits 135 136 Accrued incentive compensation 55 71 Other accrued liabilities 40 84 Total $ 525 $ 642 |
Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders | The following is a reconciliation of the numerator (net income) and denominator (number of shares) used in the calculation of basic and diluted net income per share attributable to common stockholders (in thousands): Year Ended December 31, 2021 2020 Numerator Net income $ 15,798 $ 13,298 Less: Series A accumulated dividends (2,122) (88) Less: Series B accumulated dividends (2,438) — Less: Allocation of undistributed earnings to participating securities (3,451) (4,417) Net income available to common stockholders, basic $ 7,787 $ 8,793 Add: Adjustments to undistributed earnings allocated to participating securities 181 217 Net income available to common stockholders, diluted $ 7,968 $ 9,010 Denominator Weighted average shares used in computing basic net income per share available to common stockholders 11,288 10,674 Effect of dilutive stock options 900 824 Effect of dilutive warrants 4 5 Weighted average shares used in computing diluted net income per share available to common stockholders 12,192 11,503 Basic net income per share available to common stockholders $ 0.69 $ 0.82 Diluted net income per share of common stock $ 0.65 $ 0.78 |
Outstanding Securities Considered Anti-Dilutive | The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income per share attributable to common stockholders (in thousands): Year Ended December 31, 2021 2020 Convertible preferred stock — — Common stock options 479 616 Warrants for common stock — 6 Total 479 622 |
Royalty and Commercial Paymen_2
Royalty and Commercial Payment Purchase Agreements (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Royalty and Commercial Payment Purchase Agreements | |
Summary of Acquisition of Royalty Rights | The following table summarizes the long-term royalty receivable activities including acquisitions of royalty rights, commercial payment rights and cash receipts for achievement of contractual milestones during the years ended December 31, 2021 and 2020 (in thousands): Balance at January 1, 2020 $ 34,375 Acquisition of royalty rights: Bioasis 1,200 Cash receipts for achievement of contractual milestones: Agenus (1,000) Balance at December 31, 2020 34,575 Acquisition of royalty and commercial payment rights: Viracta 13,500 Kuros 7,000 Affitech 14,000 Balance at December 31, 2021 $ 69,075 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Measurements | |
Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis | The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): Fair Value Measurements at December 31, 2021 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Assets: Equity securities $ 774 $ — $ — $ 774 Liabilities: Contingent consideration under RPAs and CPPAs $ — $ — $ 8,075 $ 8,075 Fair Value Measurements at December 31, 2020 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Assets: Equity securities $ — $ — $ 1,693 $ 1,693 Liabilities: Contingent consideration $ — $ — $ 75 $ 75 |
Summary of Changes in Estimated Fair Value of Level 3 Financial Assets | The following table reconciles the beginning and ending balance for the Level 3 financial assets recurring fair value measurement for the year ended December 31, 2021 (in thousands): Year Ended December 31, 2021 Balance at December 31, 2019 $ 681 Change in fair value 1,012 Balance at December 31, 2020 $ 1,693 Change in fair value 617 Transfer out of Level 3 as of June 30, 2021 (2,310) Balance at December 31, 2021 $ — |
Schedule of Estimated Fair Value of Equity Securities Assumptions | December 31, December 31, 2021 2020 Closing common stock price $ 4.78 $ 11.99 Tranche 1: Discount for lack of marketability N/A (1) % 12 % Estimated time to liquidity of shares 0.25 year Tranche 2: Discount for lack of marketability N/A (1) % 14 % Estimated time to liquidity of shares 0.67 years (1) Due to sufficient and consistent trading volume, the equity investment will be measured at the closing price per the Nasdaq Stock Market. The assumptions related to the unobservable inputs identified above, and any changes in those assumptions thereto, will no longer be considered in determining the fair value of the equity securities. |
Lease Agreement (Tables)
Lease Agreement (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Lease Agreement | |
Schedule of maturity of operating lease liabilities | The following table summarizes maturity of the Company’s operating lease liabilities as of December 31, 2021 (in thousands): Operating Undiscounted lease payments Leases 2022 202 2023 34 2024 — Total undiscounted lease payments 236 Present value adjustment (7) Total net lease liabilities $ 229 |
Schedule of cost components of operating leases | Operating Undiscounted lease payments Leases 2022 202 2023 34 2024 — Total undiscounted lease payments 236 Present value adjustment (7) Total net lease liabilities $ 229 |
Summary of supplemental cash flow information related to operating leases | The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Year Ended December 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows under operating leases $ 196 $ 189 |
Schedule of present value assumptions used in calculating the present value of lease payments | December 31, December 31, 2021 2020 Weighted-average remaining lease term 1.17 years 2.17 years Weighted-average discount rate 5.51 % 5.51 % |
Long-Term Debt and Other Fina_2
Long-Term Debt and Other Financings (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Long-Term Debt and Other Financings | |
Interest Expense and Amortization of Debt Issuance Costs and Discounts | Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive income for the years ended December 31, 2021 and 2020, relates to the following debt instruments (in thousands): Year Ended December 31, 2021 2020 SVB Loan $ 373 $ 1,365 Novartis Note 88 477 Other — 2 Total interest expense $ 461 $ 1,844 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Taxes | |
Schedule of Provision for Income Taxes (All Current) | The provision (benefit) for income taxes, all classified as current, consists of the following (in thousands): Year Ended December 31, 2021 2020 Federal $ 91 $ (1,501) State — — Total $ 91 $ (1,501) |
Reconciliation Between the Tax Provision Computed at the Federal Statutory Income Tax Rate and Actual Effective Income Tax Rate | Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company’s actual effective income tax rate is as follows: Year Ended December 31, 2021 2020 Federal tax at statutory rate 21 % 21 % Stock compensation and other permanent differences 9 % (6) % Federal orphan drug credit (2) % — % Tax benefit related to CARES Act — % (13) % Tax benefit related to net operating loss carryforward utilization (11) % — % Valuation allowance (16) % (15) % Total 1 % (13) % |
Components of Net Deferred Tax Assets | The significant components of net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands): December 31, 2021 2020 Capitalized research and development expenses $ 7,822 $ 11,500 Net operating loss carryforwards 17,657 17,638 Research and development and other tax credit carryforwards 13,125 13,454 Stock compensation 4,778 5,158 Unearned revenue 2,817 3,462 Other 807 401 Total deferred tax assets 47,006 51,613 Valuation allowance (47,006) (51,613) Net deferred tax assets $ — $ — |
Schedule of Unrecognized Tax Benefits | The following table summarizes the Company’s activity related to its unrecognized tax benefits (in thousands): Year Ended December 31, 2021 2020 Balance at January 1 $ 5,938 $ 5,517 Increase related to current year tax position — — Increase related to prior year tax position — 421 Balance at December 31 $ 5,938 $ 5,938 |
Stock Based Compensation (Table
Stock Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Stock Based Compensation | |
Weighted Average Assumptions | The fair value of stock options granted during the years ended December 31, 2021 and 2020, was estimated based on the following weighted average assumptions for: Year Ended December 31, 2021 2020 Dividend yield 0 % 0 % Expected volatility 83 % 100 % Risk-free interest rate 0.95 % 0.72 % Expected term 5.66 years 5.64 years |
Stock Option Activity | The following table summarizes the Company’s stock option activity for the year ended December 31, 2021. As of December 31, 2021 Weighted Weighted Average Average Aggregate Exercise Contractual Intrinsic Number of Price Term Value shares Per Share (in years) (in thousands) Outstanding at January 1, 2021 1,827,906 $ 20.66 6.31 $ 51,401 Granted 325,211 32.02 Exercised (77,305) 13.61 Forfeited, expired or cancelled (164,635) 46.59 Outstanding at December 31, 2021 1,911,177 $ 20.64 6.33 $ 15,103 Exercisable at December 31, 2021 1,553,696 $ 18.75 5.69 $ 14,894 |
Stock-based Compensation Expense | The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive income (in thousands): Year Ended December 31, 2021 2020 Research and development $ — $ — General and administrative 6,195 3,961 Total stock-based compensation expense $ 6,195 $ 3,961 |
Net Income Per Share Attribut_2
Net Income Per Share Attributable to Common Stockholders (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Net Income Per Share Attributable to Common Stockholders | |
Outstanding Securities Considered Anti-Dilutive | The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income per share attributable to common stockholders (in thousands): Year Ended December 31, 2021 2020 Convertible preferred stock — — Common stock options 479 616 Warrants for common stock — 6 Total 479 622 |
Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders | The following is a reconciliation of the numerator (net income) and denominator (number of shares) used in the calculation of basic and diluted net income per share attributable to common stockholders (in thousands): Year Ended December 31, 2021 2020 Numerator Net income $ 15,798 $ 13,298 Less: Series A accumulated dividends (2,122) (88) Less: Series B accumulated dividends (2,438) — Less: Allocation of undistributed earnings to participating securities (3,451) (4,417) Net income available to common stockholders, basic $ 7,787 $ 8,793 Add: Adjustments to undistributed earnings allocated to participating securities 181 217 Net income available to common stockholders, diluted $ 7,968 $ 9,010 Denominator Weighted average shares used in computing basic net income per share available to common stockholders 11,288 10,674 Effect of dilutive stock options 900 824 Effect of dilutive warrants 4 5 Weighted average shares used in computing diluted net income per share available to common stockholders 12,192 11,503 Basic net income per share available to common stockholders $ 0.69 $ 0.82 Diluted net income per share of common stock $ 0.65 $ 0.78 |
Capital Stock (Tables)
Capital Stock (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Capital Stock | |
Schedule of declared and paid cash dividends | Series A Preferred Stock Series B Depositary Share Cash Dividend Declared Cash Dividend Declared Dividend Declaration Date ($ per share) ($ per share) Dividend Payment Date March 17, 2021 $ 0.71875 $ N/A (1) April 15, 2021 May 21, 2021 $ 0.53906 $ 0.55833 July 15, 2021 July 28, 2021 $ 0.53906 $ 0.52344 October 15, 2021 October 20, 2021 $ 0.53906 $ 0.52344 January 18, 2022 (1) The Company sold 1,600,000 Series B Depositary Shares on April 9, 2021. As such, the first dividend was declared on May 21, 2021. |
Summary of Common Stock Warrants Outstanding | Exercise Price December 31, December 31, Issuance Date Expiration Date Balance Sheet Classification per Share 2021 2020 February 2016 February 2021 Stockholders’ equity $ 15.40 — 8,249 May 2018 May 2028 Stockholders’ equity $ 23.69 6,332 6,332 March 2019 March 2029 Stockholders’ equity $ 14.71 4,845 4,845 11,177 19,426 |
Concentration of Risk, Segmen_2
Concentration of Risk, Segment and Geographic Information (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Concentration of Risk, Segment and Geographic Information | |
Revenue by Geographical Region | Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees: Year Ended December 31, 2021 2020 Europe $ 35,000 $ 25,010 United States 2,610 1,275 Asia Pacific 550 3,100 Total $ 38,160 $ 29,385 |
Description of Business - Cash
Description of Business - Cash and Restricted Cash (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Description of Business | |||
Unrestricted and restricted cash | $ 95,377 | $ 86,364 | $ 56,688 |
Description of Business - Repay
Description of Business - Repayment of Debt (Details) $ in Millions | 1 Months Ended |
Jun. 30, 2021USD ($) | |
Silicon Valley Bank And Novartis Pharma AG | |
Long-term debt | |
Repayments of debt | $ 17.1 |
Basis of Presentation and Sig_4
Basis of Presentation and Significant Accounting Policies - Use of Estimates (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 15, 2021 | |
Basis of Presentation and Significant Accounting Policies | ||||
Contingent liabilities | $ 0 | $ 0 | $ 1,410 | $ 1,300 |
Payment of contract with customer refund liability | $ 1,300 | $ 1,305 | $ (612) |
Basis of Presentation and Sig_5
Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Basis of Presentation and Significant Accounting Policies | |||
Cash | $ 93,328 | $ 84,222 | |
Restricted cash | 2,049 | 2,142 | |
Total cash and restricted cash | $ 95,377 | $ 86,364 | $ 56,688 |
Basis of Presentation and Sig_6
Basis of Presentation and Significant Accounting Policies - Equity Securities (Details) | 1 Months Ended | |
Oct. 31, 2020shares | Sep. 30, 2020shares | |
Rezolute | ||
Equity investments | ||
Number of shares owned | 161,861 | 8,093,010 |
Rezolute | ||
Equity investments | ||
Reverse stock split | 0.02 |
Basis of Presentation and Sig_7
Basis of Presentation and Significant Accounting Policies - Purchase of Rights to Future Milestones and Royalties and Income Taxes and Net Income (Loss) per Share (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Purchase of Rights to Future Milestones and Royalties | ||
Impairment of long-term royalty receivable | $ 0 | $ 0 |
Income tax penalties or interest charged | 0 | |
Dividends declared | $ 0 |
Basis of Presentation and Sig_8
Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details) | Jan. 01, 2021 |
ASU 2019-12 | |
Adopted Accounting Pronouncements | |
Change in Accounting Principle, Accounting Standards Update, Adopted | true |
ASU 2020-06 | |
Adopted Accounting Pronouncements | |
Change in Accounting Principle, Accounting Standards Update, Adopted | true |
ASU 2020-04 | |
Adopted Accounting Pronouncements | |
Change in Accounting Principle, Accounting Standards Update, Adopted | true |
Consolidated Financial Statem_3
Consolidated Financial Statement Detail - Equity Securities (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Equity Securities | ||
Long-term equity securities | $ 1,693 | |
Gain (loss) recognized due to change in fair value of investment | $ (919) | 1,012 |
Rezolute | ||
Equity Securities | ||
Long-term equity securities | 800 | 1,700 |
Gain (loss) recognized due to change in fair value of investment | $ (900) | $ 1,000 |
Consolidated Financial Statem_4
Consolidated Financial Statement Detail - Accrued and Other Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Accrued and other liabilities | ||
Accrued legal and accounting fees | $ 295 | $ 351 |
Accrued payroll and benefits | 135 | 136 |
Accrued incentive compensation | 55 | 71 |
Other accrued liabilities | 40 | 84 |
Total | $ 525 | $ 642 |
Licensing and Other Arrangeme_2
Licensing and Other Arrangements - Novartis - NIS793 (Details) $ in Thousands | Oct. 20, 2021USD ($) | Oct. 21, 2020USD ($) | Sep. 30, 2015USD ($)item | Sep. 30, 2015USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2017USD ($) | Dec. 31, 2015USD ($) |
Licensing and other arrangements | ||||||||
Revenue from contracts with customers | $ 36,518 | $ 27,941 | ||||||
Novartis Note | ||||||||
Licensing and other arrangements | ||||||||
Reduction in debt obligation | $ 7,300 | |||||||
Novartis International | License Agreement | ||||||||
Licensing and other arrangements | ||||||||
Agreement termination prior written notice period | 180 days | |||||||
Number of performance obligations | item | 1 | |||||||
Cash payment received | 17,700 | $ 37,000 | ||||||
Revenue from contracts with customers | $ 35,000 | $ 25,000 | 35,000 | 25,000 | $ 10,000 | $ 37,000 | ||
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 410,000 | $ 480,000 | $ 480,000 | |||||
Royalty payment period | 10 years | |||||||
Contract assets | 0 | 0 | ||||||
Contract liabilities | 0 | 0 | ||||||
Capitalized contract costs | $ 0 | $ 0 |
Licensing and Other Arrangeme_3
Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details) $ / shares in Units, $ in Thousands, € in Millions | Aug. 24, 2017USD ($)itemagreement$ / sharesshares | Aug. 24, 2017EUR (€)itemagreementshares | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2017USD ($) |
Licensing and other arrangements | |||||
Revenue from contracts with customers | $ 36,518 | $ 27,941 | |||
Novartis Pharma AG [Member] | Gevokizumab License Agreement and IL-1 Target License Agreement | |||||
Licensing and other arrangements | |||||
Transaction price | $ 40,200 | ||||
Cash payment received | 25,700 | ||||
License agreement consideration received, repayment of debt | 14,300 | ||||
Common stock premium | $ 200 | ||||
Number of license agreements | agreement | 2 | 2 | |||
Number of arrangements | item | 1 | 1 | |||
Number of performance obligations | item | 2 | 2 | |||
Remaining performance obligations | 0 | ||||
Revenue from contracts with customers | 0 | 0 | $ 40,200 | ||
Contract assets | 0 | 0 | |||
Contract liabilities | 0 | 0 | |||
Capitalized contract costs | $ 0 | $ 0 | |||
Novartis Pharma AG [Member] | Gevokizumab License Agreement | |||||
Licensing and other arrangements | |||||
License agreement consideration received | $ 30,000 | ||||
Cash payment received | 15,700 | ||||
License agreement consideration received, repayment of debt | 14,300 | € 12 | |||
Proceeds from issuance of common stock | 5,000 | ||||
Common stock premium | 200 | ||||
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 438,000 | ||||
Agreement termination prior written notice period | 6 months | 6 months | |||
Novartis Pharma AG [Member] | Gevokizumab License Agreement | Common Stock | |||||
Licensing and other arrangements | |||||
Shares issued (in shares) | shares | 539,131 | 539,131 | |||
Purchase price (in dollars per share) | $ / shares | $ 9.2742 | ||||
Issuance of common stock, fair value | $ 4,800 | ||||
Closing stock price (in dollars per share) | $ / shares | $ 8.93 | ||||
Novartis Pharma AG [Member] | IL-1 Target License Agreement [Member] | |||||
Licensing and other arrangements | |||||
Cash payment received | $ 10,000 |
Licensing and Other Arrangeme_4
Licensing and Other Arrangements - Takeda (Details) - USD ($) | Nov. 16, 2020 | Feb. 28, 2009 | Nov. 30, 2006 | Dec. 31, 2021 | Dec. 31, 2020 |
Licensing and other arrangements | |||||
Revenue from contracts with customers | $ 36,518,000 | $ 27,941,000 | |||
Takeda | Collaboration agreement | |||||
Licensing and other arrangements | |||||
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | 16,000,000 | ||||
Revenue from contracts with customers | $ 2,000,000 | 100,000 | 2,100,000 | ||
Contract assets | 0 | 0 | |||
Contract liabilities | 0 | 0 | |||
Capitalized contract costs | 0 | 0 | |||
Takeda | Collaboration agreement | TAK-079 | |||||
Licensing and other arrangements | |||||
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 19,000,000 | ||||
Royalty payment period | 13 years 6 months | ||||
Takeda | Collaboration agreement | Other antibodies | |||||
Licensing and other arrangements | |||||
Maximum eligible milestone payments receivable per discovery product candidate | $ 3,300,000 | ||||
Royalty payment period | 10 years | ||||
Takeda | License Agreement | |||||
Licensing and other arrangements | |||||
Revenue from contracts with customers | $ 100,000 | $ 100,000 |
Licensing and Other Arrangeme_5
Licensing and Other Arrangements - Rezolute (Details) $ in Thousands | Dec. 06, 2017USD ($) | Oct. 31, 2020shares | Apr. 30, 2018shares | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Oct. 31, 2020USD ($)shares | Sep. 30, 2020shares |
Licensing and other arrangements | |||||||
Revenue recognized | $ 36,518 | $ 27,941 | |||||
Rezolute | |||||||
Licensing and other arrangements | |||||||
Number of shares owned | shares | 161,861 | 161,861 | 8,093,010 | ||||
Rezolute | License Agreement and Common Stock Purchase Agreement [Member] | |||||||
Licensing and other arrangements | |||||||
Payments received upon achievement of financing activities | $ 6,000 | ||||||
Installment payments received | $ 8,500 | ||||||
Number of shares received | shares | 161,861 | ||||||
Contract assets | 0 | 0 | |||||
Contract liabilities | 0 | 0 | |||||
Capitalized contract costs | 0 | 0 | |||||
Rezolute | License Agreement | |||||||
Licensing and other arrangements | |||||||
Percentage of decrease in future royalty obligations | 20.00% | ||||||
Agreement termination prior written notice period | 90 days | ||||||
Revenue recognized | $ 0 | $ 0 | |||||
Rezolute | License Agreement, RZ358 | |||||||
Licensing and other arrangements | |||||||
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 232,000 | ||||||
Royalty payment period | 12 years | ||||||
Rezolute | License Agreement, Non-RZ358 products | |||||||
Licensing and other arrangements | |||||||
Royalty payment period | 12 years | ||||||
Rezolute | |||||||
Licensing and other arrangements | |||||||
Reverse stock split | 0.02 |
Licensing and Other Arrangeme_6
Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||||
Dec. 31, 2021 | May 31, 2021 | Aug. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Licensing and other arrangements | ||||||
Revenue from contracts with customers | $ 36,518 | $ 27,941 | ||||
Janssen Biotech Inc. | License Agreement | ||||||
Licensing and other arrangements | ||||||
Cash payment received | $ 2,500 | |||||
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events | $ 3,000 | |||||
Percentage of royalty on worldwide net sales of each product upon commercialization | 0.75% | |||||
Revenue from contracts with customers | $ 200 | $ 500 | 700 | 400 | $ 2,500 | |
Contract assets | 0 | 0 | 0 | |||
Contract liabilities | 0 | 0 | 0 | |||
Capitalized contract costs | $ 0 | $ 0 | $ 0 |
Licensing and Other Arrangeme_7
Licensing and Other Arrangements - Affimed (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Licensing and other arrangements | ||
Revenue from contracts with customers | $ 36,518,000 | $ 27,941,000 |
License Agreement | Affimed | ||
Licensing and other arrangements | ||
Contract assets | 0 | |
Contract liabilities | 0 | |
Capitalized contract costs | 0 | |
Revenue from contracts with customers | $ 0 |
Licensing and Other Arrangeme_8
Licensing and Other Arrangements - NIAID (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||||||
Dec. 31, 2021 | Sep. 30, 2008 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2017 | Dec. 15, 2021 | Dec. 31, 2014 | Oct. 31, 2011 | |
Licensing and other arrangements | ||||||||
Reduction of contingent refund liability | $ 105 | |||||||
Payment of contract with customer refund liability | $ 1,300 | 1,305 | $ (612) | |||||
Revenue recognized | 36,518 | 27,941 | ||||||
Contingent liabilities | 0 | 0 | 1,410 | $ 1,300 | ||||
Arrangement with Governmental Agency | National Institute of Allergy and Infectious Diseases "NIAID" [Member] | ||||||||
Licensing and other arrangements | ||||||||
Contractual term | 3 years | |||||||
Accounts receivable | $ 400 | |||||||
Deferred revenue/Contract liabilities | $ 800 | |||||||
Accounts receivable written off | $ 400 | |||||||
Estimated refund liability | 1,300 | 1,300 | 1,400 | |||||
Reduction of contingent refund liability | 100 | |||||||
Payment of contract with customer refund liability | 1,300 | |||||||
Revenue recognized | $ (600) | |||||||
Contingent liabilities | $ 0 | $ 0 | ||||||
Arrangement with Governmental Agency, Development One | National Institute of Allergy and Infectious Diseases "NIAID" [Member] | ||||||||
Licensing and other arrangements | ||||||||
Total contract amount awarded | $ 64,800 | |||||||
Arrangement with Governmental Agency, Development Two | National Institute of Allergy and Infectious Diseases "NIAID" [Member] | ||||||||
Licensing and other arrangements | ||||||||
Total contract amount awarded | $ 28,000 |
Licensing and Other Arrangeme_9
Licensing and Other Arrangements - Sale of Future Revenue Streams (Details) $ in Thousands | Dec. 21, 2016USD ($)agreementperiod | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) |
Licensing and other arrangements | |||
Unearned revenue recognized under units-of-revenue method | $ (1,642) | $ (1,444) | |
Revenue recognized under units-of-revenue method | 1,642 | 1,444 | |
Unearned revenue recognized under units-of-revenue method, current | 1,641 | 1,452 | |
Unearned revenue recognized under units-of-revenue method, noncurrent | 11,685 | 13,516 | |
HealthCare Royalty Partners II, L.P | Royalty Sale Agreements | |||
Licensing and other arrangements | |||
Number of agreements | agreement | 2 | ||
Unearned revenue recognized under units-of-revenue method | $ 18,000 | ||
Revenue recognized under units-of-revenue method | 1,600 | 1,400 | |
Unearned revenue recognized under units-of-revenue method, current | 1,600 | 1,500 | |
Unearned revenue recognized under units-of-revenue method, noncurrent | $ 11,700 | $ 13,500 | |
HealthCare Royalty Partners II, L.P | First Royalty Sale Agreement | |||
Licensing and other arrangements | |||
Cash payment received | 6,500 | ||
Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years | $ 4,000 | ||
Number of milestone periods | period | 3 | ||
HealthCare Royalty Partners II, L.P | Second Royalty Sale Agreement | |||
Licensing and other arrangements | |||
Cash payment received | $ 11,500 |
Royalty and Commercial Paymen_3
Royalty and Commercial Payment Purchase Agreements - Agenus (Details) $ in Thousands | Sep. 20, 2018USD ($)product | Nov. 30, 2020USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Agreements | |||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 26,500 | $ 1,200 | |||
Long-term royalty and commercial payment receivables | 69,075 | 34,575 | $ 34,375 | ||
Revenue from contracts with customers | 36,518 | 27,941 | |||
Impairment of long-term royalty receivable | 0 | 0 | |||
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus [Member] | |||||
Agreements | |||||
Amount of milestone achieved | $ 10,000 | ||||
Agenus [Member] | |||||
Agreements | |||||
Cash receipts for achievement of contractual milestones | $ 1,000 | ||||
Agenus [Member] | Royalty Purchase Agreement | |||||
Agreements | |||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 15,000 | ||||
Long-term royalty and commercial payment receivables | $ 15,000 | ||||
Impairment of long-term royalty receivable | $ 0 | ||||
Agenus [Member] | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets | |||||
Agreements | |||||
Royalties entity has right to receive (as a percent) | 33.00% | ||||
Number of licensed products related to milestone and royalties | product | 6 | ||||
Purchased percentage of milestones | 10.00% | ||||
Agenus [Member] | Royalty Purchase Agreement | Merck Immuno-Oncology Product | |||||
Agreements | |||||
Royalties entity has right to receive (as a percent) | 33.00% | ||||
Purchased percentage of milestones | 10.00% | ||||
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones | $ 59,500 | ||||
Amount of milestone achieved | 1,000 | ||||
Cash receipts for achievement of contractual milestones | $ 1,000 |
Royalty and Commercial Paymen_4
Royalty and Commercial Payment Purchase Agreements - Bioasis (Details) $ in Thousands | Nov. 02, 2020USD ($) | Feb. 25, 2019USD ($)agreement | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Agreements | |||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 26,500 | $ 1,200 | |||
Long-term royalty and commercial payment receivables | 69,075 | 34,575 | $ 34,375 | ||
Contingent consideration under RPAs and CPPAs | 8,075 | 75 | |||
Impairment of long-term royalty receivable | 0 | $ 0 | |||
Bioasis | Royalty Purchase Agreement | |||||
Agreements | |||||
Percentage of option to purchase royalty right on future license agreements | 1.00% | ||||
Number of future license agreements under optional purchase right | agreement | 2 | ||||
Obligation upon exercise of options per licensed product, second agreement | $ 300 | ||||
Obligation upon exercise of options per licensed product, third agreement | 400 | ||||
Payments related to purchase of royalty rights and other commercial payment rights | 300 | ||||
Long-term royalty and commercial payment receivables | 400 | ||||
Contingent consideration under RPAs and CPPAs | 100 | 100 | |||
Changes in estimated fair value of contingent consideration | 0 | ||||
Payments of contingent consideration | 0 | ||||
Impairment of long-term royalty receivable | 0 | ||||
Bioasis | Royalty Purchase Agreement | Maximum | |||||
Agreements | |||||
Potential future cash payments | $ 200 | ||||
Bioasis | Second Royalty Purchase Agreement | |||||
Agreements | |||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 1,200 | ||||
Long-term royalty and commercial payment receivables | $ 1,200 | ||||
Impairment of long-term royalty receivable | $ 0 |
Royalty and Commercial Paymen_5
Royalty and Commercial Payment Purchase Agreements - Aronora (Details) $ in Thousands | Apr. 07, 2019USD ($)item | Sep. 30, 2019USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Agreements | |||||
Long-term royalty and commercial payment receivables | $ 69,075 | $ 34,575 | $ 34,375 | ||
Contingent consideration under RPAs and CPPAs | 8,075 | 75 | |||
Impairment of long-term royalty receivable | 0 | $ 0 | |||
Aronora | Royalty Purchase Agreement | |||||
Agreements | |||||
Number of drug candidates | item | 5 | ||||
Non-royalties to be received (as a percent) | 10.00% | ||||
Future non-royalty payments to be received (as a percent) | 5.00% | ||||
Multiplier for cumulative amount of consideration paid | item | 2 | ||||
Upfront payment | $ 6,000 | ||||
Threshold amount of cumulative royalties on net sales per product | 250,000 | ||||
Aggregate milestones payments per product | 85,000 | ||||
Long-term royalty and commercial payment receivables | 9,000 | ||||
Contingent consideration under RPAs and CPPAs | 3,000 | ||||
Payments of contingent consideration | $ 3,000 | ||||
Impairment of long-term royalty receivable | $ 0 | ||||
Aronora | Royalty Purchase Agreement | SVB Loan | |||||
Agreements | |||||
Upfront payment | $ 3,000 | ||||
Aronora | Royalty Purchase Agreement | Bayer Products | |||||
Agreements | |||||
Number of drug candidates | item | 3 | ||||
Number of drug candidates subject to exclusive license option | item | 1 | ||||
Royalties entity has right to receive (as a percent) | 100.00% | ||||
Non-royalties to be received (as a percent) | 10.00% | ||||
Contingent future cash payment for each product | $ 1,000 | ||||
Potential future cash payments | $ 3,000 | ||||
Aronora | Royalty Purchase Agreement | Non-Bayer Products | |||||
Agreements | |||||
Number of drug candidates | item | 2 | ||||
Non-royalties to be received (as a percent) | 10.00% |
Royalty and Commercial Paymen_6
Royalty and Commercial Payment Purchase Agreements - Palo (Details) | Sep. 26, 2019USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Agreements | ||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 26,500,000 | $ 1,200,000 | ||
Long-term royalty and commercial payment receivables | 69,075,000 | 34,575,000 | $ 34,375,000 | |
Impairment of long-term royalty receivable | 0 | $ 0 | ||
Palo | Royalty Purchase Agreement | ||||
Agreements | ||||
Number of drug candidates | 6 | |||
Payments related to purchase of royalty rights and other commercial payment rights | $ 10,000,000 | |||
Long-term royalty and commercial payment receivables | $ 10,000,000 | |||
Impairment of long-term royalty receivable | $ 0 |
Royalty and Commercial Paymen_7
Royalty and Commercial Payment Purchase Agreements - Viracta (Details) $ in Thousands | Mar. 22, 2021USD ($)item | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Agreements | ||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 26,500 | $ 1,200 | ||
Long-term royalty and commercial payment receivables | 69,075 | 34,575 | $ 34,375 | |
Impairment of long-term royalty receivable | 0 | $ 0 | ||
Viracta | Royalty Purchase Agreement | ||||
Agreements | ||||
Number of drug candidates | item | 2 | |||
Payments related to purchase of royalty rights and other commercial payment rights | $ 13,500 | |||
Maximum amount of potential milestones and other payments receivable | 54,000 | |||
Amount of maximum consideration retained | 20,000 | |||
Maximum amount of potential regulatory and commercial milestones receivable | 57,000 | |||
Long-term royalty and commercial payment receivables | $ 13,500 | |||
Impairment of long-term royalty receivable | $ 0 |
Royalty and Commercial Paymen_8
Royalty and Commercial Payment Purchase Agreements - Kuros (Details) - USD ($) $ in Thousands | Jul. 14, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Agreements | ||||
Long-term royalty and commercial payment receivables | $ 69,075 | $ 34,575 | $ 34,375 | |
Impairment of long-term royalty receivable | 0 | $ 0 | ||
Kuros | Royalty Purchase Agreement | ||||
Agreements | ||||
Royalties entity has right to receive (as a percent) | 100.00% | |||
Pre-commercial milestone payments | $ 25,500 | |||
Upfront payment | 7,000 | |||
Potential future sales milestone payments | 142,500 | |||
Long-term royalty and commercial payment receivables | $ 7,000 | |||
Impairment of long-term royalty receivable | $ 0 |
Royalty and Commercial Paymen_9
Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($) $ in Thousands | Oct. 06, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Agreements | ||||
Long-term royalty and commercial payment receivables | $ 69,075 | $ 34,575 | $ 34,375 | |
Contingent consideration under RPAs and CPPAs | 8,075 | 75 | ||
Impairment of long-term royalty receivable | 0 | $ 0 | ||
Affitech | Commercial payment purchase agreement | ||||
Agreements | ||||
Upfront payment | $ 6,000 | |||
Payments eligible to receive (as a percent) | 0.50% | |||
Commercial payment receivable term | 10 years | |||
Maximum additional payments upon achievement of regulatory and sales milestones | $ 20,000 | |||
Maximum payable on regulatory milestone | 8,000 | |||
Maximum payable on sales milestone | 12,000 | |||
Long-term royalty and commercial payment receivables | 14,000 | |||
Contingent consideration under RPAs and CPPAs | $ 8,000 | |||
Impairment of long-term royalty receivable | $ 0 |
Royalty and Commercial Payme_10
Royalty and Commercial Payment Purchase Agreements - Summary of Acquisition of Royalty Rights (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Agreements | ||
Balance at beginning of period | $ 34,575 | $ 34,375 |
Balance at end of period | 69,075 | 34,575 |
Agenus [Member] | ||
Agreements | ||
Cash receipts for achievement of contractual milestones | (1,000) | |
Bioasis | ||
Agreements | ||
Acquisition of royalty rights | $ 1,200 | |
Viracta | ||
Agreements | ||
Acquisition of royalty and commercial payment rights | 13,500 | |
Kuros | ||
Agreements | ||
Acquisition of royalty and commercial payment rights | 7,000 | |
Affitech | ||
Agreements | ||
Acquisition of royalty and commercial payment rights | $ 14,000 |
Fair Value Measurements - Finan
Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Transfers between Levels | ||
Transfer into Level 3 | $ 0 | |
Transfer out of Level 3 | $ 2,310,000 | 0 |
Level 1 to Level 2 transfers, Assets | 0 | |
Level 2 to Level 1 transfers, Assets | 0 | |
Level 1 to Level 2 transfers, Liabilities | 0 | |
Level 2 to Level 1 transfers, Liabilities | 0 | |
Recurring | ||
Assets: | ||
Equity securities | 774,000 | 1,693,000 |
Liabilities: | ||
Contingent consideration | 8,075,000 | 75,000 |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | ||
Assets: | ||
Equity securities | 774,000 | |
Recurring | Significant Unobservable Inputs (Level 3) | ||
Assets: | ||
Equity securities | 1,693,000 | |
Liabilities: | ||
Contingent consideration | $ 8,075,000 | $ 75,000 |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Changes In Estimated Fair Value of Level 3 Financial Assets (Details) | Jan. 01, 2020USD ($)itemshares | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) |
Changes in the estimated fair value of Level 3 financial assets | |||
Balance at beginning of period | $ 681,000 | $ 1,693,000 | $ 681,000 |
Change in fair value | 617,000 | 1,012,000 | |
Transfer out of Level 3 | $ (2,310,000) | 0 | |
Balance at end or period | $ 1,693,000 | ||
License Agreement and Common Stock Purchase Agreement [Member] | Rezolute | |||
Changes in the estimated fair value of Level 3 financial assets | |||
Number of Rezolute's post-split shares Company has right and option to sell | shares | 100,000 | ||
Number of tranches | item | 2 |
Fair Value Measurements - Estim
Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details) | Dec. 31, 2021$ / shares | Dec. 31, 2020$ / sharesY |
Rezolute | ||
Fair Value Measurements | ||
Closing stock price (in dollars per share) | $ / shares | $ 4.78 | $ 11.99 |
Closing Common Stock Price [Member] | ||
Fair Value Measurements | ||
Valuation assumptions, measurement input | $ / shares | 4.78 | 11.99 |
Discount for Lack of Marketability [Member] | Tranche 1 [Member] | ||
Fair Value Measurements | ||
Valuation assumptions, measurement input | 0.12 | |
Discount for Lack of Marketability [Member] | Tranche 2 [Member] | ||
Fair Value Measurements | ||
Valuation assumptions, measurement input | 0.14 | |
Estimated time to liquidity of shares | Tranche 1 [Member] | ||
Fair Value Measurements | ||
Valuation assumptions, measurement input | Y | 0.25 | |
Estimated time to liquidity of shares | Tranche 2 [Member] | ||
Fair Value Measurements | ||
Valuation assumptions, measurement input | Y | 0.67 |
Fair Value Measurements - Conti
Fair Value Measurements - Contingent Consideration (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Oct. 06, 2021 | Dec. 31, 2020 | Feb. 25, 2019 | |
Fair Value Measurements | ||||
Contingent consideration under RPAs and CPPAs | $ 8,075 | $ 75 | ||
Bioasis | Royalty Purchase Agreement | ||||
Fair Value Measurements | ||||
Changes in estimated fair value of contingent consideration | 0 | |||
Contingent consideration under RPAs and CPPAs | 100 | $ 100 | ||
Affitech | Royalty Purchase Agreement | ||||
Fair Value Measurements | ||||
Changes in estimated fair value of contingent consideration | 0 | |||
Contingent consideration under RPAs and CPPAs | $ 8,000 | $ 8,000 |
Lease Agreement - Leased facili
Lease Agreement - Leased facilities (Details) | 12 Months Ended |
Dec. 31, 2021facility | |
Leased facilities, Emeryville, California | |
Leases | |
Operating leases, number of leased facilities | 1 |
Lease Agreement - Maturity of l
Lease Agreement - Maturity of lease liabilities (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Lease Agreement | |
2022 | $ 202 |
2023 | 34 |
Total undiscounted lease payments | 236 |
Present value adjustment | (7) |
Total net lease liabilities | $ 229 |
Lease Agreement - Rent Expense
Lease Agreement - Rent Expense and Lease costs (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Lease costs | ||
Operating lease cost | $ 177 | $ 177 |
Variable lease cost | 8 | 7 |
Total lease costs | $ 185 | $ 184 |
Lease Agreement - Additional in
Lease Agreement - Additional information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Lease Agreement | ||
Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases | $ 196 | $ 189 |
Weighted-average remaining lease term, Operating leases | 1 year 2 months 1 day | 2 years 2 months 1 day |
Weighted-average discount rate, Operating leases | 5.51% | 5.51% |
Long-Term Debt and Other Fina_3
Long-Term Debt and Other Financings - SVB Loan (Details) - USD ($) $ / shares in Units, $ in Thousands | Mar. 07, 2018 | Jun. 30, 2021 | Mar. 31, 2019 | Sep. 30, 2018 | May 31, 2018 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Long-term debt | ||||||||
Current portion of long-term debt | $ 8,088 | |||||||
Long-term debt | $ 12,764 | |||||||
Loss on extinguishment of debt | $ (300) | |||||||
Ten Year Warrants Issued in May 2018 | ||||||||
Long-term debt | ||||||||
Exercise price of warrants (in dollars per share) | $ 23.69 | $ 23.69 | ||||||
Common stock warrant, Exercise price $14.71 per share, Issued March 2019 | ||||||||
Long-term debt | ||||||||
Exercise price of warrants (in dollars per share) | $ 14.71 | $ 14.71 | ||||||
SVB Loan | ||||||||
Long-term debt | ||||||||
Maximum borrowing capacity under loan agreement | $ 20 | |||||||
Period of monthly payments of principal and interest | 24 months | |||||||
Maximum period following loan amortization date for which loan will mature | 23 months | |||||||
Maximum period prior to loan maturity date of Novartis loan for which loan will mature | 30 days | |||||||
Repayments of debt | $ 6,500 | |||||||
Final payment fee (as a percent) | 8.50% | 8.50% | ||||||
Final payment fee | $ 1,400 | |||||||
Prepayment fee (as a percent) | 1.00% | |||||||
Exercisable period of warrants | 10 years | |||||||
Debt issuance costs | $ 200 | |||||||
Non-cash interest expense resulting from amortization of discount and accretion | $ 200 | $ 600 | ||||||
Debt amount | 0 | 11,800 | ||||||
Current portion of long-term debt | 8,100 | |||||||
Long-term debt | $ 3,700 | |||||||
Loss on extinguishment of debt | $ (300) | |||||||
SVB Loan | Minimum | ||||||||
Long-term debt | ||||||||
Interest rate (as a percent) | 4.75% | |||||||
SVB Loan | Ten Year Warrants Issued in May 2018 | ||||||||
Long-term debt | ||||||||
Aggregate number of shares of common stock called by warrants | 6,332 | |||||||
Exercise price of warrants (in dollars per share) | $ 23.69 | |||||||
Exercisable period of warrants | 10 years | |||||||
Fair value of warrant | $ 100 | |||||||
SVB Loan | Common stock warrant, Exercise price $14.71 per share, Issued March 2019 | ||||||||
Long-term debt | ||||||||
Aggregate number of shares of common stock called by warrants | 4,845 | |||||||
Exercise price of warrants (in dollars per share) | $ 14.71 | |||||||
Exercisable period of warrants | 10 years | |||||||
Fair value of warrant | $ 100 | |||||||
SVB Loan | Common stock warrant, Exercise price $23.69 per share, Issued May 2018 | ||||||||
Long-term debt | ||||||||
Aggregate number of shares of common stock called by warrants | 6,332 | |||||||
Exercise price of warrants (in dollars per share) | $ 23.69 | |||||||
Exercisable period of warrants | 10 years | |||||||
Fair value of warrant | $ 100 | |||||||
SVB Loan | Prime Rate | ||||||||
Long-term debt | ||||||||
Basis spread on variable rate | 0.25% | |||||||
SVB First Term Loan | ||||||||
Long-term debt | ||||||||
Proceeds from issuance of long-term debt | $ 7,500 | |||||||
Unamortized discount | $ 300 | |||||||
SVB Loan, Second Term Loan | ||||||||
Long-term debt | ||||||||
Proceeds from issuance of long-term debt | $ 9,500 | |||||||
Unamortized discount | $ 45,000 |
Long-Term Debt and Other Fina_4
Long-Term Debt and Other Financings - Novartis Note (Details) - USD ($) $ in Thousands | Oct. 20, 2021 | Oct. 21, 2020 | Jun. 30, 2021 | Mar. 31, 2005 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2017 | Dec. 31, 2015 | Sep. 30, 2015 |
Long-term debt | |||||||||
Revenue from contracts with customers | $ 36,518 | $ 27,941 | |||||||
Loss on extinguishment of debt | (300) | ||||||||
Novartis Note | |||||||||
Long-term debt | |||||||||
Research and development expenses funded through loan facility, maximum (as a percent) | 75.00% | ||||||||
Maximum borrowing capacity under loan agreement | $ 50,000 | ||||||||
Repayments of debt | $ 9,100 | ||||||||
Amount by which note will be reduced upon achievement of specified milestones | $ 25,000 | $ 7,300 | |||||||
Reduction in debt obligation | 7,300 | ||||||||
Debt amount | 0 | 9,100 | |||||||
Novartis Note | Six-month LIBOR | |||||||||
Long-term debt | |||||||||
Basis spread on variable rate | 2.00% | ||||||||
Novartis International | License Agreement | |||||||||
Long-term debt | |||||||||
Revenue from contracts with customers | $ 35,000 | 25,000 | $ 35,000 | $ 25,000 | $ 10,000 | $ 37,000 | |||
Cash payment received | $ 17,700 | $ 37,000 |
Long-Term Debt and Other Fina_5
Long-Term Debt and Other Financings - Interest Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Interest expense | ||
Interest expense | $ 461 | $ 1,844 |
SVB Loan | ||
Interest expense | ||
Interest expense | 373 | 1,365 |
Novartis Note | ||
Interest expense | ||
Interest expense | $ 88 | 477 |
Other | ||
Interest expense | ||
Interest expense | $ 2 |
Income Taxes - Provision for In
Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Taxes | ||
Income before income tax | $ 15,889 | $ 11,797 |
Federal | 91 | (1,501) |
Total income tax provision (benefit) | $ 91 | $ (1,501) |
Income Taxes - Reconciliation b
Income Taxes - Reconciliation between statutory rate and effective rate (Details) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2017 | |
Unrecognized tax benefits activity | |||
Federal tax at statutory rate | 21.00% | 21.00% | 34.00% |
Stock compensation and other permanent differences | 9.00% | (6.00%) | |
Federal orphan drug credit | (2.00%) | ||
Tax benefit related to CARES Act | (13.00%) | ||
Tax benefit related to net operating loss carryforward utilization | (11.00%) | ||
Valuation allowance | (16.00%) | (15.00%) | |
Total | 1.00% | (13.00%) |
Income Taxes - CARES Act (Detai
Income Taxes - CARES Act (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2017 | |
Income Taxes | |||
Federal statutory income tax rate | 21.00% | 21.00% | 34.00% |
Tax benefit related to NOL carryback provision | $ 1.5 | ||
Cash received for Cares Act income tax receivable | $ 1.5 |
Income Taxes - Components of Ne
Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Taxes | ||
Capitalized research and development expenses | $ 7,822 | $ 11,500 |
Net operating loss carryforwards | 17,657 | 17,638 |
Research and development and other tax credit carryforwards | 13,125 | 13,454 |
Stock compensation | 4,778 | 5,158 |
Unearned revenue | 2,817 | 3,462 |
Other | 807 | 401 |
Total deferred tax assets | 47,006 | 51,613 |
Valuation allowance | (47,006) | (51,613) |
(Decrease) increase in the valuation allowance | $ (4,600) | $ (3,900) |
Income Taxes - NOL (Details)
Income Taxes - NOL (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2021USD ($) | |
Federal | |
Operating Loss Carryforwards | |
Net operating loss carry-forwards | $ 78.8 |
Net operating loss carryforwards expiration year | 2036 |
Net operating loss carry forward subject to expiration | $ 13.6 |
State [Member] | |
Operating Loss Carryforwards | |
Net operating loss carry-forwards | $ 38.1 |
Net operating loss carryforwards expiration year | 2033 |
Income Taxes - Tax credit carry
Income Taxes - Tax credit carryforward (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2021USD ($) | |
Operating Loss Carryforwards | |
Operating loss carryforward offset (as a percent) | 80.00% |
Federal Orphan Credit [Member] | |
Operating Loss Carryforwards | |
Tax credit carry forward amount | $ 2 |
Tax credit carry forward expiration year | 2037 |
California [Member] | Research [Member] | |
Operating Loss Carryforwards | |
Tax credit carry forward amount | $ 19.8 |
Income Taxes - Unrecognized Tax
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Unrecognized tax benefits activity | ||
Beginning Balance | $ 5,938 | $ 5,517 |
Increase related to current year tax position | 0 | 0 |
Increase (decrease) related to prior year tax position | 421 | |
Ending Balance | 5,938 | $ 5,938 |
Unrecognized tax benefits that would impact effective tax rate | 0 | |
Unrecognized tax benefits expected to change significantly over the next twelve months | 0 | |
Accrued interest or penalties related to uncertain tax positions | $ 0 |
Stock Based Compensation - ESPP
Stock Based Compensation - ESPP (Details) - 2015 ESPP [Member] - shares | 1 Months Ended | 12 Months Ended | |||
May 31, 2017 | Dec. 31, 2021 | Dec. 31, 2020 | Apr. 30, 2017 | May 31, 2015 | |
Share-based compensation | |||||
Common stock reserved for future issuance (in shares) | 15,000 | ||||
Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions | 10.00% | ||||
Offering period | 6 months | ||||
Percentage related to employees to purchase shares at the lower fair market value at offering period | 85.00% | ||||
Shares available for purchase | 237,072 | ||||
Common Stock | |||||
Share-based compensation | |||||
Increase in aggregate number of shares authorized for issuance | 250,000 | ||||
Shares authorized for issuance | 265,000 | 15,000 | |||
Maximum shares per employee | 2,500 | ||||
Shares purchased (in shares) | 2,225 | 2,746 |
Stock Based Compensation - Defe
Stock Based Compensation - Deferred Savings Plan (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Deferred Savings Plan | ||
Maximum annual contribution per employee (as a percent) | 50.00% | 50.00% |
Age requirement for participant to be eligible for a catch-up contribution, minimum | 50 years | 50 years |
Contribution expense | $ 100 | $ 100 |
Deferred savings plan expense paid in common shares (as a percent) | 100.00% | 100.00% |
Maximum | ||
Deferred Savings Plan | ||
Employer matching contribution (as a percent) | 50.00% | 50.00% |
Employee, Under Age Fifty | ||
Deferred Savings Plan | ||
Maximum annual contribution per employee | $ 19,500 | $ 19,500 |
Employee, Age Fifty or Over | ||
Deferred Savings Plan | ||
Maximum annual contribution per employee | $ 26,000 | $ 26,000 |
Stock Based Compensation - Stoc
Stock Based Compensation - Stock Option Plans (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based compensation | ||
Number of options outstanding | 1,911,177 | 1,827,906 |
2010 Plan [Member] | ||
Share-based compensation | ||
Shares authorized for issuance | 3,029,062 | |
Expiration period | 10 years | |
2010 Plan [Member] | Minimum | Terminated employee | ||
Share-based compensation | ||
Expiration period | 3 months | |
2010 Plan [Member] | Maximum | Terminated employee | ||
Share-based compensation | ||
Expiration period | 6 months | |
2010 Plan [Member] | Stock Options [Member] | ||
Share-based compensation | ||
Shares available for grant | 161,140 |
Stock Based Compensation - St_2
Stock Based Compensation - Stock Options (Details) - Stock Options [Member] | 12 Months Ended |
Dec. 31, 2021 | |
Share-based compensation | |
Minimum age required for employees to qualify for immediate vesting of award | 55 years |
Threshold years required for retirement age | 70 years |
Employees | |
Share-based compensation | |
Vesting period | 3 years |
Directors | |
Share-based compensation | |
Vesting period | 1 year |
Stock Based Compensation - St_3
Stock Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based compensation | ||
Number of shares, Outstanding at beginning of period | 1,827,906 | |
Number of shares, Granted | 325,211 | |
Number of shares, Exercised | (77,305) | |
Number of shares, Forfeited, expired or cancelled | (164,635) | |
Number of shares, Outstanding at end of period | 1,911,177 | 1,827,906 |
Number of shares, Exercisable at end of period | 1,553,696 | |
Weighted Average Exercise Price Per Share, Outstanding at beginning of period | $ 20.66 | |
Weighted Average Exercise Price Per Share, Granted | 32.02 | |
Weighted Average Exercise Price Per Share, Exercised | 13.61 | |
Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled | 46.59 | |
Weighted Average Exercise Price Per Share, Outstanding at end of period | 20.64 | $ 20.66 |
Weighted Average Exercise Price Per Share, Exercisable at end of period | $ 18.75 | |
Weighted Average Contractual Term, Outstanding | 6 years 3 months 29 days | 6 years 3 months 21 days |
Weighted Average Contractual Term, Exercisable | 5 years 8 months 8 days | |
Aggregate Intrinsic Value, Outstanding | $ 15,103 | $ 51,401 |
Aggregate Intrinsic Value, Exercisable | 14,894 | |
Options exercised, aggregate intrinsic value | $ 1,600 | $ 5,400 |
Weighted-average grant-date fair value (in dollars per share) | $ 22.23 | $ 18.41 |
Unrecognized compensation expense related to stock options (in dollars) | $ 4,100 | |
Stock Options [Member] | ||
Share-based compensation | ||
Weighted average period of unrecognized compensation expense expected to be recognized | 2 years 2 months 15 days |
Stock Based Compensation - Weig
Stock Based Compensation - Weighted Average Assumptions (Details) - Stock Options [Member] | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Weighted average assumptions | ||
Dividend yield | 0.00% | 0.00% |
Expected volatility | 83.00% | 100.00% |
Risk-free interest rate | 0.95% | 0.72% |
Expected term | 5 years 7 months 28 days | 5 years 7 months 20 days |
Stock Based Compensation - St_4
Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based compensation expense | ||
Stock-based compensation expense | $ 6,195 | $ 3,961 |
General and Administrative [Member] | ||
Share-based compensation expense | ||
Stock-based compensation expense | $ 6,195 | $ 3,961 |
Net Income Per Share Attribut_3
Net Income Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details) - shares shares in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share | ||
Antidilutive securities excluded from computation of net loss per share (in shares) | 479 | 622 |
Common stock options | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share | ||
Antidilutive securities excluded from computation of net loss per share (in shares) | 479 | 616 |
Warrants for Common Stock [Member] | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share | ||
Antidilutive securities excluded from computation of net loss per share (in shares) | 6 |
Net Income Per Share Attribut_4
Net Income Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Numerator | ||
Net income | $ 15,798 | $ 13,298 |
Less: Allocation of undistributed earnings to participating securities | (3,451) | (4,417) |
Net (loss) income available to common stockholders, basic | 7,787 | 8,793 |
Add: Adjustments to undistributed earnings allocated to participating securities | 181 | 217 |
Net (loss) income available to common stockholders, diluted | $ 7,968 | $ 9,010 |
Denominator | ||
Weighted average shares used in computing basic net income per share available to common stockholders | 11,288 | 10,674 |
Effect of dilutive stock options | 900 | 824 |
Effect of dilutive warrants | 4 | 5 |
Weighted average shares used in computing diluted net income per share available to common stockholders | 12,192 | 11,503 |
Basic net income per share available to common stockholders (in dollars per share) | $ 0.69 | $ 0.82 |
Diluted net income per share of common stock (in dollars per share) | $ 0.65 | $ 0.78 |
8.625% Series A Cumulative, Perpetual Preferred Stock | ||
Numerator | ||
Less: Accumulated preferred dividends | $ (2,122) | $ (88) |
8.375% Series B Cumulative, Perpetual Preferred Stock | ||
Numerator | ||
Less: Accumulated preferred dividends | $ (2,438) |
Capital Stock - Series X and Se
Capital Stock - Series X and Series Y Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 12 Months Ended | |||
Feb. 28, 2017 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2021 | Dec. 31, 2020 | |
Sale of stock | |||||
Preferred stock, shares authorized (in shares) | 1,000,000 | 1,000,000 | |||
Series X And Series Y Convertible Preferred Stock | |||||
Sale of stock | |||||
Number of shares issued for each share of convertible preferred stock that is converted | 1,000 | 1,000 | |||
Series X Convertible Preferred Stock | |||||
Sale of stock | |||||
Shares issued (in shares) | 5,003 | ||||
Preferred stock, shares authorized (in shares) | 5,003 | 5,003 | |||
Preferred stock, shares issued (in shares) | 5,003 | 5,003 | |||
Preferred stock conversion price per share | $ 4.03 | ||||
Fair value of common stock amount exceeded purchase price of convertible preferred stock | $ 5.6 | ||||
Series Y Convertible Preferred Stock | |||||
Sale of stock | |||||
Shares issued (in shares) | 1,252.772 | ||||
Preferred stock, shares outstanding (in shares) | 0 | ||||
Preferred stock conversion price per share | $ 13 |
Capital Stock - Series A Prefer
Capital Stock - Series A Preferred Stock (Details) $ / shares in Units, $ in Thousands | Dec. 15, 2020USD ($)DM$ / sharesshares | Dec. 31, 2021USD ($)$ / sharesshares | Dec. 31, 2020USD ($)$ / sharesshares | Dec. 15, 2025$ / shares | Dec. 15, 2024$ / shares | Dec. 15, 2023$ / shares | Dec. 15, 2022$ / shares | Dec. 15, 2021$ / shares |
Sale of stock | ||||||||
Preferred stock, shares authorized (in shares) | shares | 1,000,000 | 1,000,000 | ||||||
Gross proceeds from issuance of preferred stock | $ | $ 40,000 | $ 24,600 | ||||||
Stock issuance costs | $ | $ 3,385 | $ 1,945 | ||||||
Preferred stock, par value (in dollars per share) | $ 0.05 | $ 0.05 | ||||||
8.625% Series A Cumulative, Perpetual Preferred Stock | ||||||||
Sale of stock | ||||||||
Preferred stock, shares authorized (in shares) | shares | 984,000 | 984,000 | ||||||
Preferred stock, shares issued (in shares) | shares | 984,000 | 984,000 | ||||||
Preferred stock, dividend rate (as a percent) | 8.625% | 8.625% | 8.625% | |||||
Purchase price (in dollars per share) | $ 25 | |||||||
Gross proceeds from issuance of preferred stock | $ | $ 24,600 | |||||||
Stock issuance costs | $ | 2,000 | |||||||
Net proceeds from issuance of stock | $ | $ 22,600 | |||||||
Liquidation preference (in dollars per share) | $ 25 | |||||||
Number of days in year over which dividend will be prorated and computed | D | 360 | |||||||
Number of months in year over which dividend will be prorated and compute | M | 12 | |||||||
Number of days in month over which dividend will be prorated and computed | D | 30 | |||||||
Preferred stock, par value (in dollars per share) | $ 0.05 | $ 0.05 | ||||||
Redemption price (in dollars per share) | $ 26 | |||||||
Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share) | $ 25 | |||||||
Share cap (in shares) | shares | 1.46071 | |||||||
Trading days | D | 10 | |||||||
8.625% Series A Cumulative, Perpetual Preferred Stock | Directors | ||||||||
Sale of stock | ||||||||
Purchase price (in dollars per share) | $ 25 | |||||||
Gross proceeds from issuance of preferred stock | $ | $ 5,000 | |||||||
8.625% Series A Cumulative, Perpetual Preferred Stock | Chief Executive Officer | ||||||||
Sale of stock | ||||||||
Purchase price (in dollars per share) | $ 25 | |||||||
Gross proceeds from issuance of preferred stock | $ | $ 200 | |||||||
Forecast | 8.625% Series A Cumulative, Perpetual Preferred Stock | ||||||||
Sale of stock | ||||||||
Redemption price (in dollars per share) | $ 25 | $ 25.25 | $ 25.50 | $ 25.75 | ||||
Preferred Stock | 8.625% Series A Cumulative, Perpetual Preferred Stock | ||||||||
Sale of stock | ||||||||
Shares issued (in shares) | shares | 984,000 | 984,000 | ||||||
Preferred Stock | 8.625% Series A Cumulative, Perpetual Preferred Stock | Directors | ||||||||
Sale of stock | ||||||||
Shares issued (in shares) | shares | 200,000 | |||||||
Preferred Stock | 8.625% Series A Cumulative, Perpetual Preferred Stock | Chief Executive Officer | ||||||||
Sale of stock | ||||||||
Shares issued (in shares) | shares | 8,000 |
Capital Stock - Series B Prefer
Capital Stock - Series B Preferred Stock (Details) $ / shares in Units, $ in Thousands | Apr. 09, 2021USD ($)DM$ / sharesshares | Dec. 31, 2021$ / sharesshares | Dec. 31, 2021USD ($)$ / sharesshares | Dec. 31, 2020USD ($)$ / sharesshares | Apr. 15, 2026$ / shares | Apr. 15, 2025$ / shares | Apr. 15, 2024$ / shares | Apr. 15, 2023$ / shares | Apr. 15, 2022$ / shares |
Sale of stock | |||||||||
Proceeds from issuance of preferred stock | $ | $ 40,000 | $ 24,600 | |||||||
Preferred stock, shares authorized (in shares) | shares | 1,000,000 | 1,000,000 | 1,000,000 | ||||||
Stock issuance costs | $ | $ 3,385 | $ 1,945 | |||||||
Preferred stock, par value (in dollars per share) | $ 0.05 | $ 0.05 | $ 0.05 | ||||||
8.375% Series B Cumulative, Perpetual Preferred Stock | |||||||||
Sale of stock | |||||||||
Preferred stock, shares authorized (in shares) | shares | 3,600 | 3,600 | |||||||
Preferred stock, shares issued (in shares) | shares | 1,600 | 1,600 | 0 | ||||||
Preferred stock, dividend rate (as a percent) | 8.375% | 8.375% | 8.375% | ||||||
Liquidation preference (in dollars per share) | $ 25,000 | ||||||||
Preferred stock, dividend amount (in dollars per share) | $ 2,093.75 | ||||||||
Number of days in year over which dividend will be prorated and computed | D | 360 | ||||||||
Number of months in year over which dividend will be prorated and compute | M | 12 | ||||||||
Number of days in month over which dividend will be prorated and computed | D | 30 | ||||||||
Preferred stock, par value (in dollars per share) | $ 0.05 | $ 0.05 | $ 0.05 | ||||||
Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share) | $ 25,000 | ||||||||
Share cap (in shares) | shares | 1,253.13 | ||||||||
8.375% Series B Cumulative, Perpetual Preferred Stock | Forecast | |||||||||
Sale of stock | |||||||||
Redemption price (in dollars per share) | $ 25,000 | $ 25,250 | $ 25,500 | $ 25,750 | $ 26,000 | ||||
Series B Depositary Shares | |||||||||
Sale of stock | |||||||||
Shares issued (in shares) | shares | 1,600,000 | ||||||||
Purchase price (in dollars per share) | $ 25 | ||||||||
Proceeds from issuance of preferred stock | $ | $ 40,000 | ||||||||
Stock issuance costs | $ | 2,900 | ||||||||
Net proceeds from issuance of preferred stock | $ | $ 37,100 | ||||||||
Share cap (in shares) | shares | 1.25313 | ||||||||
Series B Depositary Shares | Forecast | |||||||||
Sale of stock | |||||||||
Redemption price (in dollars per share) | $ 25 | $ 25.25 | $ 25.50 | $ 25.75 | $ 26 | ||||
Series B Depositary Shares | Spouse of James Neal, Chief Executive Officer and a director | |||||||||
Sale of stock | |||||||||
Shares issued (in shares) | shares | 8,000 | ||||||||
Purchase price (in dollars per share) | $ 25 | ||||||||
Proceeds from issuance of preferred stock | $ | $ 200 | ||||||||
Series B Depositary Shares | 2021 ATM Agreement | |||||||||
Sale of stock | |||||||||
Shares issued (in shares) | shares | 0 |
Capital Stock - Dividends (Deta
Capital Stock - Dividends (Details) - USD ($) $ / shares in Units, $ in Thousands | Jan. 18, 2022 | Oct. 20, 2021 | Oct. 15, 2021 | Jul. 28, 2021 | Jul. 15, 2021 | May 21, 2021 | Apr. 15, 2021 | Apr. 09, 2021 | Mar. 17, 2021 | Dec. 31, 2021 | Dec. 31, 2020 |
Dividends | |||||||||||
Restricted cash | $ 2,049 | $ 2,142 | |||||||||
8.625% Series A Cumulative, Perpetual Preferred Stock | |||||||||||
Dividends | |||||||||||
Cash dividend declared (in dollars per share) | $ 0.53906 | $ 0.53906 | $ 0.53906 | $ 0.71875 | |||||||
Cash dividend paid (in dollars per share) | $ 0.53906 | $ 0.53906 | $ 0.71875 | ||||||||
Series B Depositary Shares | |||||||||||
Dividends | |||||||||||
Cash dividend declared (in dollars per share) | $ 0.52344 | $ 0.52344 | $ 0.55833 | ||||||||
Cash dividend paid (in dollars per share) | $ 0.52344 | $ 0.55833 | |||||||||
Issuance of stock, net (in shares) | 1,600,000 | ||||||||||
Subsequent Event | 8.625% Series A Cumulative, Perpetual Preferred Stock | |||||||||||
Dividends | |||||||||||
Cash dividend paid (in dollars per share) | $ 0.53906 | ||||||||||
Subsequent Event | Series B Depositary Shares | |||||||||||
Dividends | |||||||||||
Cash dividend paid (in dollars per share) | $ 0.52344 |
Capital Stock - BVF Ownership (
Capital Stock - BVF Ownership (Details) - BVF | Dec. 31, 2021 | Feb. 29, 2020 |
Series Y Convertible Preferred Stock | ||
Sale of stock | ||
Beneficial ownership limitation (as a percent) | 50.00% | |
Xoma Corporation | Common Stock | ||
Sale of stock | ||
Ownership interest (as a percent) | 31.20% | |
Ownership interest, if shares are converted (as a percent) | 52.30% |
Capital Stock - ATM Agreements
Capital Stock - ATM Agreements (Details) - USD ($) $ in Millions | Aug. 05, 2021 | Apr. 09, 2021 | Dec. 18, 2018 | Dec. 31, 2021 | Dec. 31, 2021 | Mar. 10, 2021 |
Series B Depositary Shares | ||||||
Sale of stock | ||||||
Shares issued (in shares) | 1,600,000 | |||||
2018 Common Stock ATM Agreement | ||||||
Sale of stock | ||||||
Maximum amount of common shares to be issued | $ 30 | $ 50 | ||||
2018 Common Stock ATM Agreement | Maximum | ||||||
Sale of stock | ||||||
Sales commission paid per transaction (as a percent) | 3.00% | |||||
2021 ATM Agreement | ||||||
Sale of stock | ||||||
Maximum amount of shares to be issued | $ 50 | |||||
2021 ATM Agreement | Series B Depositary Shares | ||||||
Sale of stock | ||||||
Shares issued (in shares) | 0 | |||||
2021 ATM Agreement | Maximum | ||||||
Sale of stock | ||||||
Sales commission paid per transaction, preferred stock (as a percent) | 3.00% | |||||
Common Stock | 2018 Common Stock ATM Agreement | ||||||
Sale of stock | ||||||
Shares issued (in shares) | 0 |
Capital Stock - Summary of Comm
Capital Stock - Summary of Common Stock Warrants Outstanding (Details) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 |
Warrants | ||
Warrant outstanding (in shares) | 11,177 | 19,426 |
Five Year Warrants Issued in February 2016 | ||
Warrants | ||
Exercise price of warrants (in dollars per share) | $ 15.40 | |
Warrant outstanding (in shares) | 0 | 8,249 |
Ten Year Warrants Issued in May 2018 | ||
Warrants | ||
Exercise price of warrants (in dollars per share) | $ 23.69 | $ 23.69 |
Warrant outstanding (in shares) | 6,332 | 6,332 |
Common stock warrant, Exercise price $14.71 per share, Issued March 2019 | ||
Warrants | ||
Exercise price of warrants (in dollars per share) | $ 14.71 | $ 14.71 |
Warrant outstanding (in shares) | 4,845 | 4,845 |
Capital Stock - Common Stock Wa
Capital Stock - Common Stock Warrants (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 12 Months Ended | ||||
Feb. 28, 2021 | Mar. 31, 2019 | May 31, 2018 | Feb. 29, 2016 | Dec. 31, 2021 | Dec. 31, 2020 | |
SVB Loan | ||||||
Warrants | ||||||
Exercisable period of warrants | 10 years | |||||
Five Year Warrants Issued in February 2016 | ||||||
Warrants | ||||||
Exercise price of warrants (in dollars per share) | $ 15.40 | |||||
Five Year Warrants Issued in February 2016 | Third-Party Consultant | ||||||
Warrants | ||||||
Aggregate number of unregistered shares of common stock called by warrants (in shares) | 8,249 | |||||
Exercise price of warrants (in dollars per share) | $ 15.40 | |||||
Exercisable period of warrants | 5 years | |||||
Estimated fair value of warrants | $ 0.1 | |||||
Exercise of warrant | 4,917 | |||||
Ten Year Warrants Issued in May 2018 | ||||||
Warrants | ||||||
Exercise price of warrants (in dollars per share) | $ 23.69 | 23.69 | ||||
Ten Year Warrants Issued in May 2018 | SVB Loan | ||||||
Warrants | ||||||
Aggregate number of unregistered shares of common stock called by warrants (in shares) | 6,332 | |||||
Exercise price of warrants (in dollars per share) | $ 23.69 | |||||
Exercisable period of warrants | 10 years | |||||
Estimated fair value of warrants | $ 0.1 | |||||
Common stock warrant, Exercise price $14.71 per share, Issued March 2019 | ||||||
Warrants | ||||||
Exercise price of warrants (in dollars per share) | $ 14.71 | $ 14.71 | ||||
Common stock warrant, Exercise price $14.71 per share, Issued March 2019 | SVB Loan | ||||||
Warrants | ||||||
Aggregate number of unregistered shares of common stock called by warrants (in shares) | 4,845 | |||||
Exercise price of warrants (in dollars per share) | $ 14.71 | |||||
Exercisable period of warrants | 10 years | |||||
Estimated fair value of warrants | $ 0.1 | |||||
Exercise of warrant | 0 |
Commitments and Contingencies -
Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details) $ in Millions | Dec. 31, 2021USD ($)product |
Commitments and Contingencies | |
Estimate of milestone payments | $ | $ 6.3 |
Assumed number of products per contract | product | 1 |
Commitments and Contingencies_2
Commitments and Contingencies - Contingent Consideration (Details) - USD ($) | 1 Months Ended | 12 Months Ended | ||||
Sep. 30, 2019 | Dec. 31, 2021 | Oct. 06, 2021 | Dec. 31, 2020 | Apr. 07, 2019 | Feb. 25, 2019 | |
Commitments And Contingencies | ||||||
Contingent consideration under RPAs and CPPAs | $ 8,075,000 | $ 75,000 | ||||
Royalty Purchase Agreement | Bioasis | ||||||
Commitments And Contingencies | ||||||
Contingent consideration under RPAs and CPPAs | 100,000 | $ 100,000 | ||||
Payments of contingent consideration | 0 | |||||
Changes in estimated fair value of contingent consideration | 0 | |||||
Royalty Purchase Agreement | Aronora | ||||||
Commitments And Contingencies | ||||||
Contingent consideration under RPAs and CPPAs | $ 3,000,000 | |||||
Payments of contingent consideration | $ 3,000,000 | |||||
Royalty Purchase Agreement | Affitech | ||||||
Commitments And Contingencies | ||||||
Contingent consideration under RPAs and CPPAs | 8,000,000 | $ 8,000,000 | ||||
Changes in estimated fair value of contingent consideration | 0 | |||||
Royalty Purchase Agreement | Bioasis & Affitech | ||||||
Commitments And Contingencies | ||||||
Changes in estimated fair value of contingent consideration | 0 | |||||
Royalty Purchase Agreement | Aronora Kuros And Affitech | ||||||
Commitments And Contingencies | ||||||
Contingent consideration under RPAs and CPPAs | $ 0 |
Concentration of Risk, Segmen_3
Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details) - customer | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Customer Concentration Risk [Member] | Revenues. | ||
Concentration of Risk | ||
Number of major partners | 1 | 1 |
Customer Concentration Risk [Member] | Revenues. | Partner 1 | ||
Concentration of Risk | ||
Concentration risk (as a percent) | 92.00% | 85.00% |
Credit Concentration Risk | Accounts Receivable | ||
Concentration of Risk | ||
Number of major partners | 1 | |
Credit Concentration Risk | Accounts Receivable | Partner 1 | ||
Concentration of Risk | ||
Concentration risk (as a percent) | 100.00% |
Concentration of Risk, Segmen_4
Concentration of Risk, Segment and Geographic Information - Segment Information (Details) | 12 Months Ended |
Dec. 31, 2021segment | |
Concentration of Risk, Segment and Geographic Information | |
Number of operating segments | 1 |
Concentration of Risk, Segmen_5
Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues from External Customers | ||
Revenues | $ 38,160 | $ 29,385 |
Europe | ||
Revenues from External Customers | ||
Revenues | 35,000 | 25,010 |
Asia Pacific | ||
Revenues from External Customers | ||
Revenues | 550 | 3,100 |
United States | ||
Revenues from External Customers | ||
Revenues | $ 2,610 | $ 1,275 |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) $ in Millions | Jan. 28, 2022 | Oct. 06, 2021 | Jan. 31, 2022 |
Affitech | Commercial payment purchase agreement | |||
Subsequent Event | |||
Payments eligible to receive (as a percent) | 0.50% | ||
Commercial payment receivable term | 10 years | ||
Maximum additional payments upon achievement of regulatory and sales milestones | $ 20 | ||
Subsequent Event | Affitech | Commercial payment purchase agreement | |||
Subsequent Event | |||
Payments eligible to receive (as a percent) | 0.50% | ||
Commercial payment receivable term | 10 years | ||
Milestone payment | $ 5 | ||
Maximum additional payments upon achievement of regulatory and sales milestones | $ 15 | ||
Subsequent Event | Rezolute | License Agreement | |||
Subsequent Event | |||
Milestone payment | $ 2 |